Cabotegravir/rilpivirine (Cabenuva) vs Raltegravir

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

HIV

Shared mechanism: HIV integrase · full HIV pipeline

Cabotegravir/rilpivirine (Cabenuva)

Marketed by GlaxoSmithKline

Approved in HIVsmall molecule
Weak signal

NCT05917509 · Phase 3 · completed

The 171 participants were assigned to active treatment groups without randomization or blinding, which limits the reliability of comparisons between the regimens. The primary outcomes measured virologic suppression. Registry results were not posted at the time of grading; the key result shown was recovered from the cited external source.

Caveat: this result is taken from a company announcement or a news report of one, not from the trial registry or a peer-reviewed publication. Treat the figures as the sponsor's own statement, not as independently verified evidence.

Next expected readout: March 2027 · NCT06411223 (registry estimate)

Reported efficacy

Percentage of Participants With Plasma Human Immunodeficiency Virus-ribonucleic Acid (HIV-RNA) >=50 Copies Per Milliliter (c/mL) as Per Food and Drug Administration (FDA) Snapshot Algorithm at Week 48: HIV-1 RNA >=50 copies/mL (FDA Snapshot) at Week 48, cabotegravir LA + rilpivirine LA every 8 weeks vs every 4 weeks: 1.7% vs 1.0%, adjusted difference 0.8% (95% CI -0.6 to 2.2); non-inferior against the 4% margin (CT.gov posted results). (met)

Result source: NCT03299049

Raltegravir · Isentress

Marketed by Merck & Co.

Approved in HIVsmall molecule
Reliable signal

NCT00293254 · Phase 3 · completed

This was a randomized, double-blind, placebo-controlled trial with 351 patients, using HIV-1 RNA suppression - a regulator-accepted, disease-defining measure - as the primary endpoint. The raltegravir arm showed clearly higher suppression rates than placebo at both Week 16 and Week 48, with confidence intervals that do not overlap, indicating a statistically robust and clinically meaningful benefit.

Next expected readout: January 2028 · NCT02140255 (registry estimate)

Reported efficacy

Percentage of Participants Achieving HIV RNA <400 Copies/mL at Week 16 (16 Weeks); Percentage of Participants Achieving HIV RNA <400 Copies/mL at Week 48 (48 Weeks); Double-Blind Extension - Week 156: Percentage of Participants Achieving HIV RNA <400 Copies/mL (156 Weeks); Open-Label Extension - Week 240: Percentage of Participants Achieving HIV RNA <400 Copies/mL (240 Weeks): Percentage of Participants Achieving HIV RNA <400 Copies/mL at Week 16 (16 Weeks): Raltegravir 400 mg b.i.d. + OBT 77.3% (95% CI 71.3 to 82.6) vs Placebo + OBT 42.9% (95% CI 33.8 to 52.3) (met)

Result source: NCT00293254

Results for HIV

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointCabotegravir/​rilpivirine (Cabenuva)Raltegravir
HIV-1 RNA below 50 copies/mL (week 48)94% vs 91%vs CAB 30 mg+ABC/3TCIM-Q4W · wk 32 · n 115NCT02120352
125 other results
  • 95% vs 91% IM-Q8W · wk 32 · n 115 · Phase 2 · primary NCT02120352
  • 80% vs 71% 30 mg · wk 48 · n 60 · Phase 2 · primary NCT01641809
  • 87% vs 71% 60 mg · wk 48 · n 61 · Phase 2 · primary NCT01641809
  • 80% vs 71% 10 mg · wk 48 · n 60 · Phase 2 · primary NCT01641809
  • 52% vs 0% 30 mg · wk 312 · n 60 · Phase 2 · secondary NCT01641809
  • 60% vs 0% 30 mg · wk 300 · n 60 · Phase 2 · secondary NCT01641809
  • 62% vs 0% 30 mg · wk 288 · n 60 · Phase 2 · secondary NCT01641809
  • 62% vs 0% 30 mg · wk 276 · n 60 · Phase 2 · secondary NCT01641809
  • 62% vs 0% 30 mg · wk 264 · n 60 · Phase 2 · secondary NCT01641809
  • 62% vs 0% 30 mg · wk 252 · n 60 · Phase 2 · secondary NCT01641809
  • 62% vs 0% 30 mg · wk 240 · n 60 · Phase 2 · secondary NCT01641809
  • 63% vs 0% 30 mg · wk 228 · n 60 · Phase 2 · secondary NCT01641809
  • 63% vs 0% 30 mg · wk 216 · n 60 · Phase 2 · secondary NCT01641809
  • 62% vs 0% 30 mg · wk 204 · n 60 · Phase 2 · secondary NCT01641809
  • 65% vs 0% 30 mg · wk 192 · n 60 · Phase 2 · secondary NCT01641809
  • 67% vs 0% 30 mg · wk 180 · n 60 · Phase 2 · secondary NCT01641809
  • 65% vs 0% 30 mg · wk 168 · n 60 · Phase 2 · secondary NCT01641809
  • 63% vs 0% 30 mg · wk 156 · n 60 · Phase 2 · secondary NCT01641809
  • 67% vs 0% 30 mg · wk 144 · n 60 · Phase 2 · secondary NCT01641809
  • 70% vs 0% 30 mg · wk 132 · n 60 · Phase 2 · secondary NCT01641809
  • 73% vs 0% 30 mg · wk 120 · n 60 · Phase 2 · secondary NCT01641809
  • 72% vs 0% 30 mg · wk 108 · n 60 · Phase 2 · secondary NCT01641809
  • 75% vs 63% 30 mg · wk 96 · n 60 · Phase 2 · secondary NCT01641809
  • 85% vs 83% 30 mg · wk 96 · n 53 · Phase 2 · secondary NCT01641809
  • 75% vs 68% 30 mg · wk 84 · n 60 · Phase 2 · secondary NCT01641809
  • 85% vs 89% 30 mg · wk 84 · n 53 · Phase 2 · secondary NCT01641809
  • 73% vs 68% 30 mg · wk 72 · n 60 · Phase 2 · secondary NCT01641809
  • 83% vs 89% 30 mg · wk 72 · n 53 · Phase 2 · secondary NCT01641809
  • 73% vs 68% 30 mg · wk 60 · n 60 · Phase 2 · secondary NCT01641809
  • 83% vs 89% 30 mg · wk 60 · n 53 · Phase 2 · secondary NCT01641809
  • 80% vs 71% 30 mg · wk 48 · n 60 · Phase 2 · secondary NCT01641809
  • 91% vs 94% 30 mg · wk 48 · n 53 · Phase 2 · secondary NCT01641809
  • 82% vs 68% 30 mg · wk 40 · n 60 · Phase 2 · secondary NCT01641809
  • 92% vs 89% 30 mg · wk 40 · n 53 · Phase 2 · secondary NCT01641809
  • 82% vs 71% 30 mg · wk 36 · n 60 · Phase 2 · secondary NCT01641809
  • 92% vs 94% 30 mg · wk 36 · n 53 · Phase 2 · secondary NCT01641809
  • 80% vs 69% 30 mg · wk 32 · n 60 · Phase 2 · secondary NCT01641809
  • 91% vs 91% 30 mg · wk 32 · n 53 · Phase 2 · secondary NCT01641809
  • 78% vs 69% 30 mg · wk 28 · n 60 · Phase 2 · secondary NCT01641809
  • 89% vs 91% 30 mg · wk 28 · n 53 · Phase 2 · secondary NCT01641809
  • 75% vs 66% 30 mg · wk 26 · n 60 · Phase 2 · secondary NCT01641809
  • 85% vs 87% 30 mg · wk 26 · n 53 · Phase 2 · secondary NCT01641809
  • 85% vs 74% 30 mg · wk 24 · n 60 · Phase 2 · secondary NCT01641809
  • 94% vs 96% 30 mg · wk 24 · n 53 · Phase 2 · secondary NCT01641809
  • 70% vs 0% 60 mg · wk 312 · n 61 · Phase 2 · secondary NCT01641809
  • 70% vs 0% 60 mg · wk 300 · n 61 · Phase 2 · secondary NCT01641809
  • 74% vs 0% 60 mg · wk 288 · n 61 · Phase 2 · secondary NCT01641809
  • 70% vs 0% 60 mg · wk 276 · n 61 · Phase 2 · secondary NCT01641809
  • 75% vs 0% 60 mg · wk 264 · n 61 · Phase 2 · secondary NCT01641809
  • 75% vs 0% 60 mg · wk 252 · n 61 · Phase 2 · secondary NCT01641809
  • 74% vs 0% 60 mg · wk 240 · n 61 · Phase 2 · secondary NCT01641809
  • 75% vs 0% 60 mg · wk 228 · n 61 · Phase 2 · secondary NCT01641809
  • 77% vs 0% 60 mg · wk 216 · n 61 · Phase 2 · secondary NCT01641809
  • 75% vs 0% 60 mg · wk 204 · n 61 · Phase 2 · secondary NCT01641809
  • 74% vs 0% 60 mg · wk 192 · n 61 · Phase 2 · secondary NCT01641809
  • 75% vs 0% 60 mg · wk 180 · n 61 · Phase 2 · secondary NCT01641809
  • 75% vs 0% 60 mg · wk 168 · n 61 · Phase 2 · secondary NCT01641809
  • 80% vs 0% 60 mg · wk 156 · n 61 · Phase 2 · secondary NCT01641809
  • 77% vs 0% 60 mg · wk 144 · n 61 · Phase 2 · secondary NCT01641809
  • 80% vs 0% 60 mg · wk 132 · n 61 · Phase 2 · secondary NCT01641809
  • 80% vs 0% 60 mg · wk 120 · n 61 · Phase 2 · secondary NCT01641809
  • 80% vs 0% 60 mg · wk 108 · n 61 · Phase 2 · secondary NCT01641809
  • 84% vs 63% 60 mg · wk 96 · n 61 · Phase 2 · secondary NCT01641809
  • 93% vs 83% 60 mg · wk 96 · n 55 · Phase 2 · secondary NCT01641809
  • 85% vs 68% 60 mg · wk 84 · n 61 · Phase 2 · secondary NCT01641809
  • 95% vs 89% 60 mg · wk 84 · n 55 · Phase 2 · secondary NCT01641809
  • 85% vs 68% 60 mg · wk 72 · n 61 · Phase 2 · secondary NCT01641809
  • 95% vs 89% 60 mg · wk 72 · n 55 · Phase 2 · secondary NCT01641809
  • 85% vs 68% 60 mg · wk 60 · n 61 · Phase 2 · secondary NCT01641809
  • 95% vs 89% 60 mg · wk 60 · n 55 · Phase 2 · secondary NCT01641809
  • 87% vs 71% 60 mg · wk 48 · n 61 · Phase 2 · secondary NCT01641809
  • 96% vs 94% 60 mg · wk 48 · n 55 · Phase 2 · secondary NCT01641809
  • 85% vs 68% 60 mg · wk 40 · n 61 · Phase 2 · secondary NCT01641809
  • 95% vs 89% 60 mg · wk 40 · n 55 · Phase 2 · secondary NCT01641809
  • 85% vs 71% 60 mg · wk 36 · n 61 · Phase 2 · secondary NCT01641809
  • 95% vs 94% 60 mg · wk 36 · n 55 · Phase 2 · secondary NCT01641809
  • 87% vs 69% 60 mg · wk 32 · n 61 · Phase 2 · secondary NCT01641809
  • 96% vs 91% 60 mg · wk 32 · n 55 · Phase 2 · secondary NCT01641809
  • 85% vs 69% 60 mg · wk 28 · n 61 · Phase 2 · secondary NCT01641809
  • 95% vs 91% 60 mg · wk 28 · n 55 · Phase 2 · secondary NCT01641809
  • 85% vs 66% 60 mg · wk 26 · n 61 · Phase 2 · secondary NCT01641809
  • 95% vs 87% 60 mg · wk 26 · n 55 · Phase 2 · secondary NCT01641809
  • 87% vs 74% 60 mg · wk 24 · n 61 · Phase 2 · secondary NCT01641809
  • 96% vs 96% 60 mg · wk 24 · n 55 · Phase 2 · secondary NCT01641809
  • 52% vs 0% 10 mg · wk 312 · n 60 · Phase 2 · secondary NCT01641809
  • 52% vs 0% 10 mg · wk 300 · n 60 · Phase 2 · secondary NCT01641809
  • 50% vs 0% 10 mg · wk 288 · n 60 · Phase 2 · secondary NCT01641809
  • 52% vs 0% 10 mg · wk 276 · n 60 · Phase 2 · secondary NCT01641809
  • 53% vs 0% 10 mg · wk 264 · n 60 · Phase 2 · secondary NCT01641809
  • 52% vs 0% 10 mg · wk 252 · n 60 · Phase 2 · secondary NCT01641809
  • 50% vs 0% 10 mg · wk 240 · n 60 · Phase 2 · secondary NCT01641809
  • 53% vs 0% 10 mg · wk 228 · n 60 · Phase 2 · secondary NCT01641809
  • 55% vs 0% 10 mg · wk 216 · n 60 · Phase 2 · secondary NCT01641809
  • 55% vs 0% 10 mg · wk 204 · n 60 · Phase 2 · secondary NCT01641809
  • 57% vs 0% 10 mg · wk 192 · n 60 · Phase 2 · secondary NCT01641809
  • 58% vs 0% 10 mg · wk 180 · n 60 · Phase 2 · secondary NCT01641809
  • 57% vs 0% 10 mg · wk 168 · n 60 · Phase 2 · secondary NCT01641809
  • 58% vs 0% 10 mg · wk 156 · n 60 · Phase 2 · secondary NCT01641809
  • 58% vs 0% 10 mg · wk 144 · n 60 · Phase 2 · secondary NCT01641809
  • 62% vs 0% 10 mg · wk 132 · n 60 · Phase 2 · secondary NCT01641809
  • 65% vs 0% 10 mg · wk 120 · n 60 · Phase 2 · secondary NCT01641809
  • 68% vs 0% 10 mg · wk 108 · n 60 · Phase 2 · secondary NCT01641809
  • 68% vs 63% 10 mg · wk 96 · n 60 · Phase 2 · secondary NCT01641809
  • 79% vs 83% 10 mg · wk 96 · n 52 · Phase 2 · secondary NCT01641809
  • 72% vs 68% 10 mg · wk 84 · n 60 · Phase 2 · secondary NCT01641809
  • 83% vs 89% 10 mg · wk 84 · n 52 · Phase 2 · secondary NCT01641809
  • 72% vs 68% 10 mg · wk 72 · n 60 · Phase 2 · secondary NCT01641809
  • 83% vs 89% 10 mg · wk 72 · n 52 · Phase 2 · secondary NCT01641809
  • 78% vs 68% 10 mg · wk 60 · n 60 · Phase 2 · secondary NCT01641809
  • 90% vs 89% 10 mg · wk 60 · n 52 · Phase 2 · secondary NCT01641809
  • 80% vs 71% 10 mg · wk 48 · n 60 · Phase 2 · secondary NCT01641809
  • 92% vs 94% 10 mg · wk 48 · n 52 · Phase 2 · secondary NCT01641809
  • 83% vs 68% 10 mg · wk 40 · n 60 · Phase 2 · secondary NCT01641809
  • 96% vs 89% 10 mg · wk 40 · n 52 · Phase 2 · secondary NCT01641809
  • 85% vs 71% 10 mg · wk 36 · n 60 · Phase 2 · secondary NCT01641809
  • 98% vs 94% 10 mg · wk 36 · n 52 · Phase 2 · secondary NCT01641809
  • 83% vs 69% 10 mg · wk 32 · n 60 · Phase 2 · secondary NCT01641809
  • 96% vs 91% 10 mg · wk 32 · n 52 · Phase 2 · secondary NCT01641809
  • 85% vs 69% 10 mg · wk 28 · n 60 · Phase 2 · secondary NCT01641809
  • 98% vs 91% 10 mg · wk 28 · n 52 · Phase 2 · secondary NCT01641809
  • 78% vs 66% 10 mg · wk 26 · n 60 · Phase 2 · secondary NCT01641809
  • 90% vs 87% 10 mg · wk 26 · n 52 · Phase 2 · secondary NCT01641809
  • 87% vs 74% 10 mg · wk 24 · n 60 · Phase 2 · secondary NCT01641809
  • 96% vs 96% 10 mg · wk 24 · n 52 · Phase 2 · secondary NCT01641809
  • 98% vs 100% Q2M · wk 48 · n 90 · Phase 2 · secondary NCT03639311
—Not posted · NCT01195467
HIV-1 RNA 50 copies/mL or more (week 48)0% vs 0%vs DTG + RPVQ2M · wk 48 · n 90NCT03639311—Not posted · NCT01195467
CD4 count, change (week 48)263.7 vs 346.1vs CAB 30 mg+ABC/3TCIM-Q4W · wk 32 · n 108NCT02120352
36 other results
  • 270.6 vs 369.9 IM-Q4W · wk 96 · n 108 · Phase 2 · secondary NCT02120352
  • 264.4 vs 346.1 IM-Q8W · wk 32 · n 112 · Phase 2 · secondary NCT02120352
  • 257.5 vs 369.9 IM-Q8W · wk 96 · n 112 · Phase 2 · secondary NCT02120352
  • 241.6 vs 262.5 30 mg · wk 48 · n 60 · Phase 2 · secondary NCT01641809
  • 212.8 vs 221.5 30 mg · wk 40 · n 60 · Phase 2 · secondary NCT01641809
  • 213 vs 185.2 30 mg · wk 36 · n 60 · Phase 2 · secondary NCT01641809
  • 269.4 vs 263.8 30 mg · wk 60 · n 60 · Phase 2 · secondary NCT01641809
  • 205.2 vs 197.4 30 mg · wk 32 · n 60 · Phase 2 · secondary NCT01641809
  • 188.1 vs 178.2 30 mg · wk 28 · n 60 · Phase 2 · secondary NCT01641809
  • 177.7 vs 166.4 30 mg · wk 26 · n 60 · Phase 2 · secondary NCT01641809
  • 180.9 vs 143.4 30 mg · wk 24 · n 60 · Phase 2 · secondary NCT01641809
  • 201.4 vs 257.1 30 mg · wk 72 · n 60 · Phase 2 · secondary NCT01641809
  • 287 vs 279.4 30 mg · wk 84 · n 60 · Phase 2 · secondary NCT01641809
  • 267.5 vs 281.7 30 mg · wk 96 · n 60 · Phase 2 · secondary NCT01641809
  • 259 vs 262.5 60 mg · wk 48 · n 61 · Phase 2 · secondary NCT01641809
  • 212.3 vs 221.5 60 mg · wk 40 · n 61 · Phase 2 · secondary NCT01641809
  • 265 vs 185.2 60 mg · wk 36 · n 61 · Phase 2 · secondary NCT01641809
  • 266.1 vs 263.8 60 mg · wk 60 · n 61 · Phase 2 · secondary NCT01641809
  • 209.9 vs 197.4 60 mg · wk 32 · n 61 · Phase 2 · secondary NCT01641809
  • 193.3 vs 178.2 60 mg · wk 28 · n 61 · Phase 2 · secondary NCT01641809
  • 194.7 vs 166.4 60 mg · wk 26 · n 61 · Phase 2 · secondary NCT01641809
  • 204 vs 143.4 60 mg · wk 24 · n 61 · Phase 2 · secondary NCT01641809
  • 254 vs 257.1 60 mg · wk 72 · n 61 · Phase 2 · secondary NCT01641809
  • 278.1 vs 279.4 60 mg · wk 84 · n 61 · Phase 2 · secondary NCT01641809
  • 286.2 vs 281.7 60 mg · wk 96 · n 61 · Phase 2 · secondary NCT01641809
  • 235.1 vs 262.5 10 mg · wk 48 · n 60 · Phase 2 · secondary NCT01641809
  • 203.6 vs 221.5 10 mg · wk 40 · n 60 · Phase 2 · secondary NCT01641809
  • 192 vs 185.2 10 mg · wk 36 · n 60 · Phase 2 · secondary NCT01641809
  • 217.7 vs 263.8 10 mg · wk 60 · n 60 · Phase 2 · secondary NCT01641809
  • 191.4 vs 197.4 10 mg · wk 32 · n 60 · Phase 2 · secondary NCT01641809
  • 205 vs 178.2 10 mg · wk 28 · n 60 · Phase 2 · secondary NCT01641809
  • 186.4 vs 166.4 10 mg · wk 26 · n 60 · Phase 2 · secondary NCT01641809
  • 172.5 vs 143.4 10 mg · wk 24 · n 60 · Phase 2 · secondary NCT01641809
  • 232 vs 257.1 10 mg · wk 72 · n 60 · Phase 2 · secondary NCT01641809
  • 261.5 vs 279.4 10 mg · wk 84 · n 60 · Phase 2 · secondary NCT01641809
  • 269.4 vs 281.7 10 mg · wk 96 · n 60 · Phase 2 · secondary NCT01641809
98.4 vs 39.8+58.6 vs placebo400 mg b.i.d. · wk 48 · n 217NCT00293254
6 other results
  • 120.2 vs 49.4 400 mg b.i.d · wk 48 · n 230 · Phase 3 · secondary NCT00293267
  • 157.2 vs 54.2 400 mg b.i.d. · wk 156 · n 189 · Phase 3 · secondary NCT00293254
  • 170.9 vs 71.0 400 mg b.i.d · wk 156 · n 207 · Phase 3 · secondary NCT00293267
  • 8.6 vs 21.9 wk 24 · n 19 · Phase 4 · primary NCT00772590
  • 2.7 vs 21.9 wk 24 · n 19 · Phase 4 · primary NCT00772590
  • 192 vs 205 wk 48 · n 9 · Phase 4 · primary NCT00762892

HIV-1 RNA below 50 copies/mL (week 48)

Cabotegravir/​rilpivirine (Cabenuva)
94% vs 91%vs CAB 30 mg+ABC/3TCIM-Q4W · wk 32 · n 115NCT02120352
125 other results
  • 95% vs 91% IM-Q8W · wk 32 · n 115 · Phase 2 · primary NCT02120352
  • 80% vs 71% 30 mg · wk 48 · n 60 · Phase 2 · primary NCT01641809
  • 87% vs 71% 60 mg · wk 48 · n 61 · Phase 2 · primary NCT01641809
  • 80% vs 71% 10 mg · wk 48 · n 60 · Phase 2 · primary NCT01641809
  • 52% vs 0% 30 mg · wk 312 · n 60 · Phase 2 · secondary NCT01641809
  • 60% vs 0% 30 mg · wk 300 · n 60 · Phase 2 · secondary NCT01641809
  • 62% vs 0% 30 mg · wk 288 · n 60 · Phase 2 · secondary NCT01641809
  • 62% vs 0% 30 mg · wk 276 · n 60 · Phase 2 · secondary NCT01641809
  • 62% vs 0% 30 mg · wk 264 · n 60 · Phase 2 · secondary NCT01641809
  • 62% vs 0% 30 mg · wk 252 · n 60 · Phase 2 · secondary NCT01641809
  • 62% vs 0% 30 mg · wk 240 · n 60 · Phase 2 · secondary NCT01641809
  • 63% vs 0% 30 mg · wk 228 · n 60 · Phase 2 · secondary NCT01641809
  • 63% vs 0% 30 mg · wk 216 · n 60 · Phase 2 · secondary NCT01641809
  • 62% vs 0% 30 mg · wk 204 · n 60 · Phase 2 · secondary NCT01641809
  • 65% vs 0% 30 mg · wk 192 · n 60 · Phase 2 · secondary NCT01641809
  • 67% vs 0% 30 mg · wk 180 · n 60 · Phase 2 · secondary NCT01641809
  • 65% vs 0% 30 mg · wk 168 · n 60 · Phase 2 · secondary NCT01641809
  • 63% vs 0% 30 mg · wk 156 · n 60 · Phase 2 · secondary NCT01641809
  • 67% vs 0% 30 mg · wk 144 · n 60 · Phase 2 · secondary NCT01641809
  • 70% vs 0% 30 mg · wk 132 · n 60 · Phase 2 · secondary NCT01641809
  • 73% vs 0% 30 mg · wk 120 · n 60 · Phase 2 · secondary NCT01641809
  • 72% vs 0% 30 mg · wk 108 · n 60 · Phase 2 · secondary NCT01641809
  • 75% vs 63% 30 mg · wk 96 · n 60 · Phase 2 · secondary NCT01641809
  • 85% vs 83% 30 mg · wk 96 · n 53 · Phase 2 · secondary NCT01641809
  • 75% vs 68% 30 mg · wk 84 · n 60 · Phase 2 · secondary NCT01641809
  • 85% vs 89% 30 mg · wk 84 · n 53 · Phase 2 · secondary NCT01641809
  • 73% vs 68% 30 mg · wk 72 · n 60 · Phase 2 · secondary NCT01641809
  • 83% vs 89% 30 mg · wk 72 · n 53 · Phase 2 · secondary NCT01641809
  • 73% vs 68% 30 mg · wk 60 · n 60 · Phase 2 · secondary NCT01641809
  • 83% vs 89% 30 mg · wk 60 · n 53 · Phase 2 · secondary NCT01641809
  • 80% vs 71% 30 mg · wk 48 · n 60 · Phase 2 · secondary NCT01641809
  • 91% vs 94% 30 mg · wk 48 · n 53 · Phase 2 · secondary NCT01641809
  • 82% vs 68% 30 mg · wk 40 · n 60 · Phase 2 · secondary NCT01641809
  • 92% vs 89% 30 mg · wk 40 · n 53 · Phase 2 · secondary NCT01641809
  • 82% vs 71% 30 mg · wk 36 · n 60 · Phase 2 · secondary NCT01641809
  • 92% vs 94% 30 mg · wk 36 · n 53 · Phase 2 · secondary NCT01641809
  • 80% vs 69% 30 mg · wk 32 · n 60 · Phase 2 · secondary NCT01641809
  • 91% vs 91% 30 mg · wk 32 · n 53 · Phase 2 · secondary NCT01641809
  • 78% vs 69% 30 mg · wk 28 · n 60 · Phase 2 · secondary NCT01641809
  • 89% vs 91% 30 mg · wk 28 · n 53 · Phase 2 · secondary NCT01641809
  • 75% vs 66% 30 mg · wk 26 · n 60 · Phase 2 · secondary NCT01641809
  • 85% vs 87% 30 mg · wk 26 · n 53 · Phase 2 · secondary NCT01641809
  • 85% vs 74% 30 mg · wk 24 · n 60 · Phase 2 · secondary NCT01641809
  • 94% vs 96% 30 mg · wk 24 · n 53 · Phase 2 · secondary NCT01641809
  • 70% vs 0% 60 mg · wk 312 · n 61 · Phase 2 · secondary NCT01641809
  • 70% vs 0% 60 mg · wk 300 · n 61 · Phase 2 · secondary NCT01641809
  • 74% vs 0% 60 mg · wk 288 · n 61 · Phase 2 · secondary NCT01641809
  • 70% vs 0% 60 mg · wk 276 · n 61 · Phase 2 · secondary NCT01641809
  • 75% vs 0% 60 mg · wk 264 · n 61 · Phase 2 · secondary NCT01641809
  • 75% vs 0% 60 mg · wk 252 · n 61 · Phase 2 · secondary NCT01641809
  • 74% vs 0% 60 mg · wk 240 · n 61 · Phase 2 · secondary NCT01641809
  • 75% vs 0% 60 mg · wk 228 · n 61 · Phase 2 · secondary NCT01641809
  • 77% vs 0% 60 mg · wk 216 · n 61 · Phase 2 · secondary NCT01641809
  • 75% vs 0% 60 mg · wk 204 · n 61 · Phase 2 · secondary NCT01641809
  • 74% vs 0% 60 mg · wk 192 · n 61 · Phase 2 · secondary NCT01641809
  • 75% vs 0% 60 mg · wk 180 · n 61 · Phase 2 · secondary NCT01641809
  • 75% vs 0% 60 mg · wk 168 · n 61 · Phase 2 · secondary NCT01641809
  • 80% vs 0% 60 mg · wk 156 · n 61 · Phase 2 · secondary NCT01641809
  • 77% vs 0% 60 mg · wk 144 · n 61 · Phase 2 · secondary NCT01641809
  • 80% vs 0% 60 mg · wk 132 · n 61 · Phase 2 · secondary NCT01641809
  • 80% vs 0% 60 mg · wk 120 · n 61 · Phase 2 · secondary NCT01641809
  • 80% vs 0% 60 mg · wk 108 · n 61 · Phase 2 · secondary NCT01641809
  • 84% vs 63% 60 mg · wk 96 · n 61 · Phase 2 · secondary NCT01641809
  • 93% vs 83% 60 mg · wk 96 · n 55 · Phase 2 · secondary NCT01641809
  • 85% vs 68% 60 mg · wk 84 · n 61 · Phase 2 · secondary NCT01641809
  • 95% vs 89% 60 mg · wk 84 · n 55 · Phase 2 · secondary NCT01641809
  • 85% vs 68% 60 mg · wk 72 · n 61 · Phase 2 · secondary NCT01641809
  • 95% vs 89% 60 mg · wk 72 · n 55 · Phase 2 · secondary NCT01641809
  • 85% vs 68% 60 mg · wk 60 · n 61 · Phase 2 · secondary NCT01641809
  • 95% vs 89% 60 mg · wk 60 · n 55 · Phase 2 · secondary NCT01641809
  • 87% vs 71% 60 mg · wk 48 · n 61 · Phase 2 · secondary NCT01641809
  • 96% vs 94% 60 mg · wk 48 · n 55 · Phase 2 · secondary NCT01641809
  • 85% vs 68% 60 mg · wk 40 · n 61 · Phase 2 · secondary NCT01641809
  • 95% vs 89% 60 mg · wk 40 · n 55 · Phase 2 · secondary NCT01641809
  • 85% vs 71% 60 mg · wk 36 · n 61 · Phase 2 · secondary NCT01641809
  • 95% vs 94% 60 mg · wk 36 · n 55 · Phase 2 · secondary NCT01641809
  • 87% vs 69% 60 mg · wk 32 · n 61 · Phase 2 · secondary NCT01641809
  • 96% vs 91% 60 mg · wk 32 · n 55 · Phase 2 · secondary NCT01641809
  • 85% vs 69% 60 mg · wk 28 · n 61 · Phase 2 · secondary NCT01641809
  • 95% vs 91% 60 mg · wk 28 · n 55 · Phase 2 · secondary NCT01641809
  • 85% vs 66% 60 mg · wk 26 · n 61 · Phase 2 · secondary NCT01641809
  • 95% vs 87% 60 mg · wk 26 · n 55 · Phase 2 · secondary NCT01641809
  • 87% vs 74% 60 mg · wk 24 · n 61 · Phase 2 · secondary NCT01641809
  • 96% vs 96% 60 mg · wk 24 · n 55 · Phase 2 · secondary NCT01641809
  • 52% vs 0% 10 mg · wk 312 · n 60 · Phase 2 · secondary NCT01641809
  • 52% vs 0% 10 mg · wk 300 · n 60 · Phase 2 · secondary NCT01641809
  • 50% vs 0% 10 mg · wk 288 · n 60 · Phase 2 · secondary NCT01641809
  • 52% vs 0% 10 mg · wk 276 · n 60 · Phase 2 · secondary NCT01641809
  • 53% vs 0% 10 mg · wk 264 · n 60 · Phase 2 · secondary NCT01641809
  • 52% vs 0% 10 mg · wk 252 · n 60 · Phase 2 · secondary NCT01641809
  • 50% vs 0% 10 mg · wk 240 · n 60 · Phase 2 · secondary NCT01641809
  • 53% vs 0% 10 mg · wk 228 · n 60 · Phase 2 · secondary NCT01641809
  • 55% vs 0% 10 mg · wk 216 · n 60 · Phase 2 · secondary NCT01641809
  • 55% vs 0% 10 mg · wk 204 · n 60 · Phase 2 · secondary NCT01641809
  • 57% vs 0% 10 mg · wk 192 · n 60 · Phase 2 · secondary NCT01641809
  • 58% vs 0% 10 mg · wk 180 · n 60 · Phase 2 · secondary NCT01641809
  • 57% vs 0% 10 mg · wk 168 · n 60 · Phase 2 · secondary NCT01641809
  • 58% vs 0% 10 mg · wk 156 · n 60 · Phase 2 · secondary NCT01641809
  • 58% vs 0% 10 mg · wk 144 · n 60 · Phase 2 · secondary NCT01641809
  • 62% vs 0% 10 mg · wk 132 · n 60 · Phase 2 · secondary NCT01641809
  • 65% vs 0% 10 mg · wk 120 · n 60 · Phase 2 · secondary NCT01641809
  • 68% vs 0% 10 mg · wk 108 · n 60 · Phase 2 · secondary NCT01641809
  • 68% vs 63% 10 mg · wk 96 · n 60 · Phase 2 · secondary NCT01641809
  • 79% vs 83% 10 mg · wk 96 · n 52 · Phase 2 · secondary NCT01641809
  • 72% vs 68% 10 mg · wk 84 · n 60 · Phase 2 · secondary NCT01641809
  • 83% vs 89% 10 mg · wk 84 · n 52 · Phase 2 · secondary NCT01641809
  • 72% vs 68% 10 mg · wk 72 · n 60 · Phase 2 · secondary NCT01641809
  • 83% vs 89% 10 mg · wk 72 · n 52 · Phase 2 · secondary NCT01641809
  • 78% vs 68% 10 mg · wk 60 · n 60 · Phase 2 · secondary NCT01641809
  • 90% vs 89% 10 mg · wk 60 · n 52 · Phase 2 · secondary NCT01641809
  • 80% vs 71% 10 mg · wk 48 · n 60 · Phase 2 · secondary NCT01641809
  • 92% vs 94% 10 mg · wk 48 · n 52 · Phase 2 · secondary NCT01641809
  • 83% vs 68% 10 mg · wk 40 · n 60 · Phase 2 · secondary NCT01641809
  • 96% vs 89% 10 mg · wk 40 · n 52 · Phase 2 · secondary NCT01641809
  • 85% vs 71% 10 mg · wk 36 · n 60 · Phase 2 · secondary NCT01641809
  • 98% vs 94% 10 mg · wk 36 · n 52 · Phase 2 · secondary NCT01641809
  • 83% vs 69% 10 mg · wk 32 · n 60 · Phase 2 · secondary NCT01641809
  • 96% vs 91% 10 mg · wk 32 · n 52 · Phase 2 · secondary NCT01641809
  • 85% vs 69% 10 mg · wk 28 · n 60 · Phase 2 · secondary NCT01641809
  • 98% vs 91% 10 mg · wk 28 · n 52 · Phase 2 · secondary NCT01641809
  • 78% vs 66% 10 mg · wk 26 · n 60 · Phase 2 · secondary NCT01641809
  • 90% vs 87% 10 mg · wk 26 · n 52 · Phase 2 · secondary NCT01641809
  • 87% vs 74% 10 mg · wk 24 · n 60 · Phase 2 · secondary NCT01641809
  • 96% vs 96% 10 mg · wk 24 · n 52 · Phase 2 · secondary NCT01641809
  • 98% vs 100% Q2M · wk 48 · n 90 · Phase 2 · secondary NCT03639311
Raltegravir
—Not posted · NCT01195467

HIV-1 RNA 50 copies/mL or more (week 48)

Cabotegravir/​rilpivirine (Cabenuva)
0% vs 0%vs DTG + RPVQ2M · wk 48 · n 90NCT03639311
Raltegravir
—Not posted · NCT01195467

CD4 count, change (week 48)

Cabotegravir/​rilpivirine (Cabenuva)
263.7 vs 346.1vs CAB 30 mg+ABC/3TCIM-Q4W · wk 32 · n 108NCT02120352
36 other results
  • 270.6 vs 369.9 IM-Q4W · wk 96 · n 108 · Phase 2 · secondary NCT02120352
  • 264.4 vs 346.1 IM-Q8W · wk 32 · n 112 · Phase 2 · secondary NCT02120352
  • 257.5 vs 369.9 IM-Q8W · wk 96 · n 112 · Phase 2 · secondary NCT02120352
  • 241.6 vs 262.5 30 mg · wk 48 · n 60 · Phase 2 · secondary NCT01641809
  • 212.8 vs 221.5 30 mg · wk 40 · n 60 · Phase 2 · secondary NCT01641809
  • 213 vs 185.2 30 mg · wk 36 · n 60 · Phase 2 · secondary NCT01641809
  • 269.4 vs 263.8 30 mg · wk 60 · n 60 · Phase 2 · secondary NCT01641809
  • 205.2 vs 197.4 30 mg · wk 32 · n 60 · Phase 2 · secondary NCT01641809
  • 188.1 vs 178.2 30 mg · wk 28 · n 60 · Phase 2 · secondary NCT01641809
  • 177.7 vs 166.4 30 mg · wk 26 · n 60 · Phase 2 · secondary NCT01641809
  • 180.9 vs 143.4 30 mg · wk 24 · n 60 · Phase 2 · secondary NCT01641809
  • 201.4 vs 257.1 30 mg · wk 72 · n 60 · Phase 2 · secondary NCT01641809
  • 287 vs 279.4 30 mg · wk 84 · n 60 · Phase 2 · secondary NCT01641809
  • 267.5 vs 281.7 30 mg · wk 96 · n 60 · Phase 2 · secondary NCT01641809
  • 259 vs 262.5 60 mg · wk 48 · n 61 · Phase 2 · secondary NCT01641809
  • 212.3 vs 221.5 60 mg · wk 40 · n 61 · Phase 2 · secondary NCT01641809
  • 265 vs 185.2 60 mg · wk 36 · n 61 · Phase 2 · secondary NCT01641809
  • 266.1 vs 263.8 60 mg · wk 60 · n 61 · Phase 2 · secondary NCT01641809
  • 209.9 vs 197.4 60 mg · wk 32 · n 61 · Phase 2 · secondary NCT01641809
  • 193.3 vs 178.2 60 mg · wk 28 · n 61 · Phase 2 · secondary NCT01641809
  • 194.7 vs 166.4 60 mg · wk 26 · n 61 · Phase 2 · secondary NCT01641809
  • 204 vs 143.4 60 mg · wk 24 · n 61 · Phase 2 · secondary NCT01641809
  • 254 vs 257.1 60 mg · wk 72 · n 61 · Phase 2 · secondary NCT01641809
  • 278.1 vs 279.4 60 mg · wk 84 · n 61 · Phase 2 · secondary NCT01641809
  • 286.2 vs 281.7 60 mg · wk 96 · n 61 · Phase 2 · secondary NCT01641809
  • 235.1 vs 262.5 10 mg · wk 48 · n 60 · Phase 2 · secondary NCT01641809
  • 203.6 vs 221.5 10 mg · wk 40 · n 60 · Phase 2 · secondary NCT01641809
  • 192 vs 185.2 10 mg · wk 36 · n 60 · Phase 2 · secondary NCT01641809
  • 217.7 vs 263.8 10 mg · wk 60 · n 60 · Phase 2 · secondary NCT01641809
  • 191.4 vs 197.4 10 mg · wk 32 · n 60 · Phase 2 · secondary NCT01641809
  • 205 vs 178.2 10 mg · wk 28 · n 60 · Phase 2 · secondary NCT01641809
  • 186.4 vs 166.4 10 mg · wk 26 · n 60 · Phase 2 · secondary NCT01641809
  • 172.5 vs 143.4 10 mg · wk 24 · n 60 · Phase 2 · secondary NCT01641809
  • 232 vs 257.1 10 mg · wk 72 · n 60 · Phase 2 · secondary NCT01641809
  • 261.5 vs 279.4 10 mg · wk 84 · n 60 · Phase 2 · secondary NCT01641809
  • 269.4 vs 281.7 10 mg · wk 96 · n 60 · Phase 2 · secondary NCT01641809
Raltegravir
98.4 vs 39.8+58.6 vs placebo400 mg b.i.d. · wk 48 · n 217NCT00293254
6 other results
  • 120.2 vs 49.4 400 mg b.i.d · wk 48 · n 230 · Phase 3 · secondary NCT00293267
  • 157.2 vs 54.2 400 mg b.i.d. · wk 156 · n 189 · Phase 3 · secondary NCT00293254
  • 170.9 vs 71.0 400 mg b.i.d · wk 156 · n 207 · Phase 3 · secondary NCT00293267
  • 8.6 vs 21.9 wk 24 · n 19 · Phase 4 · primary NCT00772590
  • 2.7 vs 21.9 wk 24 · n 19 · Phase 4 · primary NCT00772590
  • 192 vs 205 wk 48 · n 9 · Phase 4 · primary NCT00762892
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
3 other shared endpoints and safety

Coverage. Cabotegravir/rilpivirine (Cabenuva): 7 of 7 rows · Raltegravir: 7 of 7 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.

Reported metricCabotegravir/​rilpivirine (Cabenuva)
Rows use multiple source trials
Raltegravir
Rows use multiple source trials
CD4+
absolute change · cells/uL
Induction
142.2 vs 135.5 Efavirenz cells/uL @ 16wk30 mga,b,c,d
NCT01641809 · Phase 2 · registry result, not featured evidence · pooled
show 2 more doses
148.3 vs 135.5 Efavirenz cells/uL @ 16wk60 mg
NCT01641809 · Phase 2 · registry result, not featured evidence · pooled
159.3 vs 135.5 Efavirenz cells/uL @ 16wk10 mg
NCT01641809 · Phase 2 · registry result, not featured evidence · pooled
85.8 vs 39.9 placebo cells/uL @ 16wk400 mg b.i.d.b,c,d
NCT00293254 · Phase 3 · combination
1 other source trial
82.7 vs 31.3 placebo cells/uL @ 16wk400 mg b.i.d
NCT00293267 · Phase 3 · combination
CD4+
absolute change · cells/uL
No placebo or comparator arm
276 cells/uL @ 324wk30 mga,b,c,e,f
NCT01641809 · Phase 2 · registry result, not featured evidence · pooled
show 2 more doses
272 cells/uL @ 324wk60 mg
NCT01641809 · Phase 2 · registry result, not featured evidence · pooled
402 cells/uL @ 324wk10 mg
NCT01641809 · Phase 2 · registry result, not featured evidence · pooled
261.6 cells/uL @ 96wkb,c,e,f
NCT02131233 · Phase 3 · registry result, not featured evidence
HIV-1 RNA LT 50 Copies
responder rate · % of participants
No placebo or comparator arm
100% (n=115) @ 130wkg,h,e,i
NCT04001803 · Phase 3 · registry result, not featured evidence
90.6% (n=32) @ 96wkg,h,e,i
NCT00939874 · Phase 4 · registry result, not featured evidence
Dropout rate
13.6%j
NCT04982445 · Phase 4 · registry result, not featured evidence
show 45 more results
—400 mg + 600 mg Q4W
NCT05896748 · Phase 3 · registry result, not featured evidence · combination
—400 mg + 600 mg Q4W
NCT05896748 · Phase 3 · registry result, not featured evidence · combination
—400 mg + 600 mg Q4W
NCT05896748 · Phase 3 · registry result, not featured evidence · combination
1.1%400 mg + 600 mg Q4W
NCT05896748 · Phase 3 · registry result, not featured evidence · combination
8.6%Direct to Injections (D2I)
NCT04542070 · Phase 3 · registry result, not featured evidence
13.1%Oral lead-in Phase (OLI)
NCT04542070 · Phase 3 · registry result, not featured evidence
—Q2M
NCT04542070 · Phase 3 · registry result, not featured evidence
6.5%
NCT04399551 · Phase 3 · registry result, not featured evidence
11.3%
NCT04001803 · Phase 3 · registry result, not featured evidence
1.3%CAB LA + VRC07-523LS
NCT03739996 · Phase 2 · registry result, not featured evidence · combination
—Step 2: CAB LA + VRC07-523LS
NCT03739996 · Phase 2 · registry result, not featured evidence · combination
—IM-Q4W
NCT02120352 · Phase 2 · registry result, not featured evidence · combination
—IM-Q4W
NCT02120352 · Phase 2 · registry result, not featured evidence · combination
—IM-Q8W
NCT02120352 · Phase 2 · registry result, not featured evidence · combination
—IM-Q8W
NCT02120352 · Phase 2 · registry result, not featured evidence · combination
15.6%Q2M
NCT03639311 · Phase 2 · registry result, not featured evidence · combination
11.7%30 mg
NCT01641809 · Phase 2 · registry result, not featured evidence · pooled
—30 mg
NCT01641809 · Phase 2 · registry result, not featured evidence
—30 mg
NCT01641809 · Phase 2 · registry result, not featured evidence
—30 mg
NCT01641809 · Phase 2 · registry result, not featured evidence
9.8%60 mg
NCT01641809 · Phase 2 · registry result, not featured evidence · pooled
—60 mg
NCT01641809 · Phase 2 · registry result, not featured evidence
—60 mg
NCT01641809 · Phase 2 · registry result, not featured evidence
—60 mg
NCT01641809 · Phase 2 · registry result, not featured evidence
13.3%10 mg
NCT01641809 · Phase 2 · registry result, not featured evidence · pooled
—10 mg
NCT01641809 · Phase 2 · registry result, not featured evidence
—10 mg
NCT01641809 · Phase 2 · registry result, not featured evidence
—10 mg
NCT01641809 · Phase 2 · registry result, not featured evidence
12.5%30 mg
NCT00920426 · Phase 2 · registry result, not featured evidence
—5 mg
NCT00920426 · Phase 2 · registry result, not featured evidence
15.2%30 mg
NCT04484337 · Phase 1 · registry result, not featured evidence
—Part 1: Cohort 1 (C1) CAB200
NCT04484337 · Phase 1 · registry result, not featured evidence
—Part 1: Cohort 1 (C1) CAB400
NCT04484337 · Phase 1 · registry result, not featured evidence
—Part 1: Cohort 2 (C2) CAB200
NCT04484337 · Phase 1 · registry result, not featured evidence
—Part 1: Cohort 2 (C2) CAB400
NCT04484337 · Phase 1 · registry result, not featured evidence
—Part 1: Cohort 3 (C3) CAB200
NCT04484337 · Phase 1 · registry result, not featured evidence
—Part 1: Cohort 3 (C3) CAB400
NCT04484337 · Phase 1 · registry result, not featured evidence
—Part 1: Cohort 4 (C4) CAB200
NCT04484337 · Phase 1 · registry result, not featured evidence
—Part 1: Cohort 4 (C4) CAB400
NCT04484337 · Phase 1 · registry result, not featured evidence
—Part 1: Cohort 4h (C4h) CAB200 + r
NCT04484337 · Phase 1 · registry result, not featured evidence · combination
—Part 1: Cohort 4h (C4h) CAB400 + r
NCT04484337 · Phase 1 · registry result, not featured evidence · combination
—Part 2: Cohort 5 (C5) CAB200
NCT04484337 · Phase 1 · registry result, not featured evidence
—Part 2: Cohort 5 (C5) CAB400
NCT04484337 · Phase 1 · registry result, not featured evidence
—30 mg
NCT03149848 · Phase 1 · registry result, not featured evidence
—300 mg + 30 mg
NCT03149848 · Phase 1 · registry result, not featured evidence · combination
23.7%400 mg b.i.d.j
NCT00293254 · Phase 3 · combination
show 27 more results
—400 mg b.i.d.
NCT00293254 · Phase 3 · combination
—400 mg b.i.d
NCT00293267 · Phase 3 · combination
17.5%400 mg b.i.d
NCT00293267 · Phase 3 · combination
25.5%400 mg b.i.d.
NCT00369941 · Phase 3
15.4%
NCT01147107 · Phase 4 · registry result, not featured evidence
9.5%
NCT03374358 · Phase 4 · registry result, not featured evidence
0%
NCT03667547 · Phase 4 · registry result, not featured evidence
—Arm A Raltegravir
NCT03205566 · Phase 4 · registry result, not featured evidence
—Arm B Raltegravir Lamivudine
NCT03205566 · Phase 4 · registry result, not featured evidence · combination
10.5%
NCT02383355 · Phase 4 · registry result, not featured evidence
38.5%
NCT00939874 · Phase 4 · registry result, not featured evidence
0%
NCT00843713 · Phase 4 · registry result, not featured evidence
22.2%
NCT01332227 · Phase 4 · registry result, not featured evidence · combination
27.3%
NCT00870363 · Phase 4 · registry result, not featured evidence · combination
6.7%Switch to Tenofovir/Emtricitabine
NCT01270802 · Phase 4 · registry result, not featured evidence · combination
—Switch to Tenofovir/Emtricitabine/
NCT01270802 · Phase 4 · registry result, not featured evidence
35.7%
NCT00762892 · Phase 4 · registry result, not featured evidence
0%
NCT01335620 · Phase 4 · registry result, not featured evidence · combination
6.7%Intervention Arm No.1
NCT00931801 · Phase 4 · registry result, not featured evidence · combination
28.6%Intervention Arm No.2
NCT00931801 · Phase 4 · registry result, not featured evidence · combination
0%Hyper-immune Bovine Colostrum
NCT00772590 · Phase 4 · registry result, not featured evidence
0%Raltegravir + Hyper-immune Bovine
NCT00772590 · Phase 4 · registry result, not featured evidence · combination
0%
NCT00631449 · Phase 4 · registry result, not featured evidence
7.5%1200 mg QD
NCT03029689 · Phase 3 · registry result, not featured evidence · combination
4.1%
NCT02284035 · Phase 3 · registry result, not featured evidence · combination
—1200 mg QD + Truvada
NCT02131233 · Phase 3 · registry result, not featured evidence · combination
12.4%Reformulated Raltegravir
NCT02131233 · Phase 3 · registry result, not featured evidence
Discontinued due to AEs
—j
NCT04982445 · Phase 4 · registry result, not featured evidence
show 45 more results
—400 mg + 600 mg Q4W
NCT05896748 · Phase 3 · registry result, not featured evidence · combination
—400 mg + 600 mg Q4W
NCT05896748 · Phase 3 · registry result, not featured evidence · combination
—400 mg + 600 mg Q4W
NCT05896748 · Phase 3 · registry result, not featured evidence · combination
—400 mg + 600 mg Q4W
NCT05896748 · Phase 3 · registry result, not featured evidence · combination
1.1%Direct to Injections (D2I)
NCT04542070 · Phase 3 · registry result, not featured evidence
5.7%Oral lead-in Phase (OLI)
NCT04542070 · Phase 3 · registry result, not featured evidence
—Q2M
NCT04542070 · Phase 3 · registry result, not featured evidence
3.5%
NCT04399551 · Phase 3 · registry result, not featured evidence
4.3%
NCT04001803 · Phase 3 · registry result, not featured evidence
—CAB LA + VRC07-523LS
NCT03739996 · Phase 2 · registry result, not featured evidence · combination
—Step 2: CAB LA + VRC07-523LS
NCT03739996 · Phase 2 · registry result, not featured evidence · combination
—IM-Q4W
NCT02120352 · Phase 2 · registry result, not featured evidence · combination
—IM-Q4W
NCT02120352 · Phase 2 · registry result, not featured evidence · combination
—IM-Q8W
NCT02120352 · Phase 2 · registry result, not featured evidence · combination
—IM-Q8W
NCT02120352 · Phase 2 · registry result, not featured evidence · combination
1.1%Q2M
NCT03639311 · Phase 2 · registry result, not featured evidence · combination
1.7%30 mg
NCT01641809 · Phase 2 · registry result, not featured evidence · pooled
—30 mg
NCT01641809 · Phase 2 · registry result, not featured evidence
—30 mg
NCT01641809 · Phase 2 · registry result, not featured evidence
—30 mg
NCT01641809 · Phase 2 · registry result, not featured evidence
4.9%60 mg
NCT01641809 · Phase 2 · registry result, not featured evidence · pooled
—60 mg
NCT01641809 · Phase 2 · registry result, not featured evidence
—60 mg
NCT01641809 · Phase 2 · registry result, not featured evidence
—60 mg
NCT01641809 · Phase 2 · registry result, not featured evidence
0%10 mg
NCT01641809 · Phase 2 · registry result, not featured evidence · pooled
—10 mg
NCT01641809 · Phase 2 · registry result, not featured evidence
—10 mg
NCT01641809 · Phase 2 · registry result, not featured evidence
—10 mg
NCT01641809 · Phase 2 · registry result, not featured evidence
12.5%30 mg
NCT00920426 · Phase 2 · registry result, not featured evidence
—5 mg
NCT00920426 · Phase 2 · registry result, not featured evidence
—30 mg
NCT04484337 · Phase 1 · registry result, not featured evidence
—Part 1: Cohort 1 (C1) CAB200
NCT04484337 · Phase 1 · registry result, not featured evidence
—Part 1: Cohort 1 (C1) CAB400
NCT04484337 · Phase 1 · registry result, not featured evidence
—Part 1: Cohort 2 (C2) CAB200
NCT04484337 · Phase 1 · registry result, not featured evidence
—Part 1: Cohort 2 (C2) CAB400
NCT04484337 · Phase 1 · registry result, not featured evidence
—Part 1: Cohort 3 (C3) CAB200
NCT04484337 · Phase 1 · registry result, not featured evidence
—Part 1: Cohort 3 (C3) CAB400
NCT04484337 · Phase 1 · registry result, not featured evidence
—Part 1: Cohort 4 (C4) CAB200
NCT04484337 · Phase 1 · registry result, not featured evidence
—Part 1: Cohort 4 (C4) CAB400
NCT04484337 · Phase 1 · registry result, not featured evidence
—Part 1: Cohort 4h (C4h) CAB200 + r
NCT04484337 · Phase 1 · registry result, not featured evidence · combination
—Part 1: Cohort 4h (C4h) CAB400 + r
NCT04484337 · Phase 1 · registry result, not featured evidence · combination
—Part 2: Cohort 5 (C5) CAB200
NCT04484337 · Phase 1 · registry result, not featured evidence
—Part 2: Cohort 5 (C5) CAB400
NCT04484337 · Phase 1 · registry result, not featured evidence
—30 mg
NCT03149848 · Phase 1 · registry result, not featured evidence
—300 mg + 30 mg
NCT03149848 · Phase 1 · registry result, not featured evidence · combination
0.9%400 mg b.i.d.j
NCT00293254 · Phase 3 · combination
show 27 more results
—400 mg b.i.d.
NCT00293254 · Phase 3 · combination
—400 mg b.i.d
NCT00293267 · Phase 3 · combination
0.4%400 mg b.i.d
NCT00293267 · Phase 3 · combination
5%400 mg b.i.d.
NCT00369941 · Phase 3
—
NCT01147107 · Phase 4 · registry result, not featured evidence
—
NCT03374358 · Phase 4 · registry result, not featured evidence
—
NCT03667547 · Phase 4 · registry result, not featured evidence
—Arm A Raltegravir
NCT03205566 · Phase 4 · registry result, not featured evidence
—Arm B Raltegravir Lamivudine
NCT03205566 · Phase 4 · registry result, not featured evidence · combination
10.5%
NCT02383355 · Phase 4 · registry result, not featured evidence
—
NCT00939874 · Phase 4 · registry result, not featured evidence
—
NCT00843713 · Phase 4 · registry result, not featured evidence
5.6%
NCT01332227 · Phase 4 · registry result, not featured evidence · combination
—
NCT00870363 · Phase 4 · registry result, not featured evidence · combination
0%Switch to Tenofovir/Emtricitabine
NCT01270802 · Phase 4 · registry result, not featured evidence · combination
—Switch to Tenofovir/Emtricitabine/
NCT01270802 · Phase 4 · registry result, not featured evidence
—
NCT00762892 · Phase 4 · registry result, not featured evidence
—
NCT01335620 · Phase 4 · registry result, not featured evidence · combination
0%Intervention Arm No.1
NCT00931801 · Phase 4 · registry result, not featured evidence · combination
7.1%Intervention Arm No.2
NCT00931801 · Phase 4 · registry result, not featured evidence · combination
—Hyper-immune Bovine Colostrum
NCT00772590 · Phase 4 · registry result, not featured evidence
—Raltegravir + Hyper-immune Bovine
NCT00772590 · Phase 4 · registry result, not featured evidence · combination
—
NCT00631449 · Phase 4 · registry result, not featured evidence
—1200 mg QD
NCT03029689 · Phase 3 · registry result, not featured evidence · combination
—
NCT02284035 · Phase 3 · registry result, not featured evidence · combination
—1200 mg QD + Truvada
NCT02131233 · Phase 3 · registry result, not featured evidence · combination
1.3%Reformulated Raltegravir
NCT02131233 · Phase 3 · registry result, not featured evidence
Serious AEs
0%j
NCT04982445 · Phase 4 · registry result, not featured evidence
show 45 more results
0%400 mg + 600 mg Q4W
NCT05896748 · Phase 3 · registry result, not featured evidence · combination
0%400 mg + 600 mg Q4W
NCT05896748 · Phase 3 · registry result, not featured evidence · combination
1.1%400 mg + 600 mg Q4W
NCT05896748 · Phase 3 · registry result, not featured evidence · combination
—400 mg + 600 mg Q4W
NCT05896748 · Phase 3 · registry result, not featured evidence · combination
3.6%Direct to Injections (D2I)
NCT04542070 · Phase 3 · registry result, not featured evidence
6.3%Oral lead-in Phase (OLI)
NCT04542070 · Phase 3 · registry result, not featured evidence
3.4%Q2M
NCT04542070 · Phase 3 · registry result, not featured evidence
4%
NCT04399551 · Phase 3 · registry result, not featured evidence
7.8%
NCT04001803 · Phase 3 · registry result, not featured evidence
—CAB LA + VRC07-523LS
NCT03739996 · Phase 2 · registry result, not featured evidence · combination
12.7%Step 2: CAB LA + VRC07-523LS
NCT03739996 · Phase 2 · registry result, not featured evidence · combination
27%IM-Q4W
NCT02120352 · Phase 2 · registry result, not featured evidence · combination
10%IM-Q4W
NCT02120352 · Phase 2 · registry result, not featured evidence · combination
27%IM-Q8W
NCT02120352 · Phase 2 · registry result, not featured evidence · combination
26.5%IM-Q8W
NCT02120352 · Phase 2 · registry result, not featured evidence · combination
11.1%Q2M
NCT03639311 · Phase 2 · registry result, not featured evidence · combination
—30 mg
NCT01641809 · Phase 2 · registry result, not featured evidence · pooled
0%30 mg
NCT01641809 · Phase 2 · registry result, not featured evidence
9.4%30 mg
NCT01641809 · Phase 2 · registry result, not featured evidence
17%30 mg
NCT01641809 · Phase 2 · registry result, not featured evidence
—60 mg
NCT01641809 · Phase 2 · registry result, not featured evidence · pooled
3.3%60 mg
NCT01641809 · Phase 2 · registry result, not featured evidence
9.1%60 mg
NCT01641809 · Phase 2 · registry result, not featured evidence
9.8%60 mg
NCT01641809 · Phase 2 · registry result, not featured evidence
—10 mg
NCT01641809 · Phase 2 · registry result, not featured evidence · pooled
3.3%10 mg
NCT01641809 · Phase 2 · registry result, not featured evidence
9.6%10 mg
NCT01641809 · Phase 2 · registry result, not featured evidence
15.2%10 mg
NCT01641809 · Phase 2 · registry result, not featured evidence
0%30 mg
NCT00920426 · Phase 2 · registry result, not featured evidence
0%5 mg
NCT00920426 · Phase 2 · registry result, not featured evidence
0%30 mg
NCT04484337 · Phase 1 · registry result, not featured evidence
0%Part 1: Cohort 1 (C1) CAB200
NCT04484337 · Phase 1 · registry result, not featured evidence
0%Part 1: Cohort 1 (C1) CAB400
NCT04484337 · Phase 1 · registry result, not featured evidence
0%Part 1: Cohort 2 (C2) CAB200
NCT04484337 · Phase 1 · registry result, not featured evidence
0%Part 1: Cohort 2 (C2) CAB400
NCT04484337 · Phase 1 · registry result, not featured evidence
0%Part 1: Cohort 3 (C3) CAB200
NCT04484337 · Phase 1 · registry result, not featured evidence
12.5%Part 1: Cohort 3 (C3) CAB400
NCT04484337 · Phase 1 · registry result, not featured evidence
0%Part 1: Cohort 4 (C4) CAB200
NCT04484337 · Phase 1 · registry result, not featured evidence
0%Part 1: Cohort 4 (C4) CAB400
NCT04484337 · Phase 1 · registry result, not featured evidence
0%Part 1: Cohort 4h (C4h) CAB200 + r
NCT04484337 · Phase 1 · registry result, not featured evidence · combination
0%Part 1: Cohort 4h (C4h) CAB400 + r
NCT04484337 · Phase 1 · registry result, not featured evidence · combination
0%Part 2: Cohort 5 (C5) CAB200
NCT04484337 · Phase 1 · registry result, not featured evidence
0%Part 2: Cohort 5 (C5) CAB400
NCT04484337 · Phase 1 · registry result, not featured evidence
0%30 mg
NCT03149848 · Phase 1 · registry result, not featured evidence
7.1%300 mg + 30 mg
NCT03149848 · Phase 1 · registry result, not featured evidence · combination
—400 mg b.i.d.j
NCT00293254 · Phase 3 · combination
show 27 more results
34.8%400 mg b.i.d.
NCT00293254 · Phase 3 · combination
41.8%400 mg b.i.d
NCT00293267 · Phase 3 · combination
—400 mg b.i.d
NCT00293267 · Phase 3 · combination
20.3%400 mg b.i.d.
NCT00369941 · Phase 3
21.1%
NCT01147107 · Phase 4 · registry result, not featured evidence
0%
NCT03374358 · Phase 4 · registry result, not featured evidence
0%
NCT03667547 · Phase 4 · registry result, not featured evidence
0%Arm A Raltegravir
NCT03205566 · Phase 4 · registry result, not featured evidence
0%Arm B Raltegravir Lamivudine
NCT03205566 · Phase 4 · registry result, not featured evidence · combination
0%
NCT02383355 · Phase 4 · registry result, not featured evidence
13.5%
NCT00939874 · Phase 4 · registry result, not featured evidence
3.8%
NCT00843713 · Phase 4 · registry result, not featured evidence
5.6%
NCT01332227 · Phase 4 · registry result, not featured evidence · combination
0%
NCT00870363 · Phase 4 · registry result, not featured evidence · combination
—Switch to Tenofovir/Emtricitabine
NCT01270802 · Phase 4 · registry result, not featured evidence · combination
0%Switch to Tenofovir/Emtricitabine/
NCT01270802 · Phase 4 · registry result, not featured evidence
7.1%
NCT00762892 · Phase 4 · registry result, not featured evidence
0%
NCT01335620 · Phase 4 · registry result, not featured evidence · combination
13.3%Intervention Arm No.1
NCT00931801 · Phase 4 · registry result, not featured evidence · combination
14.3%Intervention Arm No.2
NCT00931801 · Phase 4 · registry result, not featured evidence · combination
0%Hyper-immune Bovine Colostrum
NCT00772590 · Phase 4 · registry result, not featured evidence
5.3%Raltegravir + Hyper-immune Bovine
NCT00772590 · Phase 4 · registry result, not featured evidence · combination
0%
NCT00631449 · Phase 4 · registry result, not featured evidence
0%1200 mg QD
NCT03029689 · Phase 3 · registry result, not featured evidence · combination
6.1%
NCT02284035 · Phase 3 · registry result, not featured evidence · combination
9.6%1200 mg QD + Truvada
NCT02131233 · Phase 3 · registry result, not featured evidence · combination
—Reformulated Raltegravir
NCT02131233 · Phase 3 · registry result, not featured evidence
Most frequent reported AEs
j
injection site discomfort 13.6%
injection site pain 13.6%
fatigue 2.3%
NCT04982445 · Phase 4 · registry result, not featured evidence
show 40 more results
400 mg + 600 mg Q4W
injection site pain 32.3%
injection site nodule 9.7%
injection site induration 2.2%
NCT05896748 · Phase 3 · registry result, not featured evidence · combination
400 mg + 600 mg Q4W
injection site pain 74.2%
injection site nodule 64.5%
injection site erythema 51.6%
NCT05896748 · Phase 3 · registry result, not featured evidence · combination
400 mg + 600 mg Q4W
injection site pain 30.9%
injection site nodule 3.2%
injection site pruritus 2.1%
NCT05896748 · Phase 3 · registry result, not featured evidence · combination
injection site pain 65.2%
covid-19 17.9%
headache 12.5%
NCT04542070 · Phase 3 · registry result, not featured evidence
injection site pain 60.6%
covid-19 19.4%
injection site induration 11.4%
NCT04542070 · Phase 3 · registry result, not featured evidence
Q2M
injection site pain 37.9%
covid-19 14.5%
arthralgia 0%
NCT04542070 · Phase 3 · registry result, not featured evidence
injection site pain 80.2%
covid-19 18.4%
injection site induration 11.2%
NCT04399551 · Phase 3 · registry result, not featured evidence
injection site pain 55.7%
injection site discomfort 26.1%
fatigue 20%
NCT04001803 · Phase 3 · registry result, not featured evidence
creatinine renal clearance decreased 19.7%
lipase increased 11.3%
chills 7%
NCT03739996 · Phase 2 · registry result, not featured evidence · combination
IM-Q4W
injection site pain 99.1%
injection site nodule 49.6%
nasopharyngitis 47%
NCT02120352 · Phase 2 · registry result, not featured evidence · combination
IM-Q4W
injection site pain 80%
injection site nodule 50%
nasopharyngitis 50%
NCT02120352 · Phase 2 · registry result, not featured evidence · combination
IM-Q8W
injection site pain 96.5%
nasopharyngitis 47%
injection site nodule 40%
NCT02120352 · Phase 2 · registry result, not featured evidence · combination
IM-Q8W
injection site pain 91.2%
injection site nodule 35.3%
covid-19 26.5%
NCT02120352 · Phase 2 · registry result, not featured evidence · combination
Q2M
injection site pain 74.4%
covid-19 33.3%
upper respiratory tract infection 17.8%
NCT03639311 · Phase 2 · registry result, not featured evidence · combination
30 mg
headache 21.7%
nausea 18.3%
upper respiratory tract infection 13.3%
NCT01641809 · Phase 2 · registry result, not featured evidence
30 mg
upper respiratory tract infection 26.4%
diarrhoea 13.2%
rash 11.3%
NCT01641809 · Phase 2 · registry result, not featured evidence
30 mg
upper respiratory tract infection 31.9%
back pain 12.8%
oropharyngeal pain 12.8%
NCT01641809 · Phase 2 · registry result, not featured evidence
60 mg
headache 21.3%
diarrhoea 18%
nausea 18%
NCT01641809 · Phase 2 · registry result, not featured evidence
60 mg
upper respiratory tract infection 21.8%
nausea 14.5%
bronchitis 10.9%
NCT01641809 · Phase 2 · registry result, not featured evidence
60 mg
upper respiratory tract infection 27.5%
anxiety 11.8%
sinusitis 11.8%
NCT01641809 · Phase 2 · registry result, not featured evidence
10 mg
nausea 23.3%
headache 21.7%
diarrhoea 16.7%
NCT01641809 · Phase 2 · registry result, not featured evidence
10 mg
upper respiratory tract infection 17.3%
depression 9.6%
diarrhoea 9.6%
NCT01641809 · Phase 2 · registry result, not featured evidence
10 mg
diarrhoea 13%
nasopharyngitis 10.9%
gonorrhoea 8.7%
NCT01641809 · Phase 2 · registry result, not featured evidence
30 mg
dizziness 37.5% (placebo 0%)
dyspepsia 25% (placebo 0%)
headache 25% (placebo 0%)
NCT00920426 · Phase 2 · registry result, not featured evidence
5 mg
abdominal pain 0% (placebo 0%)
abnormal dreams 0% (placebo 0%)
blood bilirubin increased 0% (placebo 50%)
NCT00920426 · Phase 2 · registry result, not featured evidence
30 mg
atrioventricular block first degree 7.7%
decreased appetite 7.7%
headache 7.7%
NCT04484337 · Phase 1 · registry result, not featured evidence
injection site pain 100%
aspartate aminotransferase increased 50%
blood creatine phosphokinase increased 50%
NCT04484337 · Phase 1 · registry result, not featured evidence
injection site pain 100%
injection site nodule 55.6%
injection site erythema 44.4%
NCT04484337 · Phase 1 · registry result, not featured evidence
injection site haemorrhage 100%
injection site nodule 100%
injection site pain 100%
NCT04484337 · Phase 1 · registry result, not featured evidence
injection site erythema 72.7%
injection site pain 72.7%
injection site induration 45.5%
NCT04484337 · Phase 1 · registry result, not featured evidence
injection site induration 100%
injection site pain 100%
injection site bruising 50%
NCT04484337 · Phase 1 · registry result, not featured evidence
injection site pain 75%
headache 37.5%
injection site swelling 37.5%
NCT04484337 · Phase 1 · registry result, not featured evidence
catheter site bruise 50%
injection site erythema 50%
injection site induration 50%
NCT04484337 · Phase 1 · registry result, not featured evidence
injection site erythema 100%
injection site pain 94.4%
headache 77.8%
NCT04484337 · Phase 1 · registry result, not featured evidence
injection site erythema 100%
injection site pain 100%
injection site pruritus 87.5%
NCT04484337 · Phase 1 · registry result, not featured evidence · combination
injection site erythema 100%
injection site pain 100%
injection site warmth 88.9%
NCT04484337 · Phase 1 · registry result, not featured evidence · combination
accident 100%
injection site nodule 100%
injection site pain 100%
NCT04484337 · Phase 1 · registry result, not featured evidence
injection site pain 100%
injection site swelling 70%
headache 60%
NCT04484337 · Phase 1 · registry result, not featured evidence
30 mg
blood creatine phosphokinase increased 6.7%
contusion 6.7%
body temperature increased 0%
NCT03149848 · Phase 1 · registry result, not featured evidence
300 mg + 30 mg
body temperature increased 7.1%
headache 7.1%
hyperkeratosis 7.1%
NCT03149848 · Phase 1 · registry result, not featured evidence · combination
400 mg b.i.d.j
upper respiratory tract infection 33% (placebo 24.4%)
diarrhoea 32.6% (placebo 29.4%)
fatigue 19.6% (placebo 15.1%)
NCT00293254 · Phase 3 · combination
show 17 more results
400 mg b.i.d
diarrhoea 31.9% (placebo 28.8%)
nasopharyngitis 25% (placebo 17.8%)
bronchitis 18.1% (placebo 13.6%)
NCT00293267 · Phase 3 · combination
400 mg b.i.d.
nasopharyngitis 26.7%
headache 26%
diarrhoea 25.6%
NCT00369941 · Phase 3
alt elevation 55.3%
NCT01147107 · Phase 4 · registry result, not featured evidence
sleeping difficulties 52.6% (placebo 54.2%)
gastrointestinal (diarrhoea, nausea) 47.4% (placebo 29.2%)
headache 47.4% (placebo 33.3%)
NCT03374358 · Phase 4 · registry result, not featured evidence
runny nose 10.5%
cold 5.3%
diarrhoea 5.3%
NCT03205566 · Phase 4 · registry result, not featured evidence
nightmares and vivid dreams 13.2%
diarrhoea 7.9%
headache 7.9%
NCT03205566 · Phase 4 · registry result, not featured evidence · combination
headache 5.3%
insomnia 5.3%
NCT02383355 · Phase 4 · registry result, not featured evidence
upper respiratory tract infection 18.9%
diarrhoea 10.8%
abdominal cramps 5.4%
NCT00939874 · Phase 4 · registry result, not featured evidence
hyperbilirubinemia 3.8% (placebo 0%)
NCT00843713 · Phase 4 · registry result, not featured evidence
hyperbilirubinaemia 8.3%
ocular icterus 8.3%
bronchitis 5.6%
NCT01332227 · Phase 4 · registry result, not featured evidence · combination
gastrointestinal intolerance 9.1%
neuropsychiatric side effect 0%
NCT00870363 · Phase 4 · registry result, not featured evidence · combination
neutropenia 6.7%
diastolic hypertension 0%
impaired fasting glucose 0%
NCT01270802 · Phase 4 · registry result, not featured evidence
bronchitis 20%
diarrhea 20%
headache 20%
NCT00931801 · Phase 4 · registry result, not featured evidence · combination
diarrhea 21.4%
upper respiratory infection 21.4%
fatigue 14.3%
NCT00931801 · Phase 4 · registry result, not featured evidence · combination
1200 mg QD
adverse event not related to the treatment 2.6% (placebo 5.6%)
NCT03029689 · Phase 3 · registry result, not featured evidence · combination
insomnia 8.2%
amigdalitis 6.1%
common cold 6.1%
NCT02284035 · Phase 3 · registry result, not featured evidence · combination
1200 mg QD + Truvada
headache 15.8%
nausea 13.6%
diarrhoea 13.4%
NCT02131233 · Phase 3 · registry result, not featured evidence · combination

Notes

  1. aThis study reports multiple eligible drug arms; no representative arm has been reviewed.
  2. bTrial phases differ: Phase 2 versus Phase 3.
  3. cPopulation comparability has not been reviewed for both studies.
  4. dTreatment context differs: pooled versus combination.
  5. eTreatment context has not been resolved for both arms.
  6. fAssessment timepoints differ: 324 weeks versus 96 weeks.
  7. gTrial phases differ: Phase 3 versus Phase 4.
  8. hPopulation context differs: registered conditions differ.
  9. iAssessment timepoints differ: 130 weeks versus 96 weeks.
  10. jPopulation comparability has not been reviewed for these studies.

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

Cabotegravir/rilpivirine (Cabenuva)

HIV-1 RNA Less Than 50 Copies Per 100% (n=93) @ 4wk400 mg + 600 mg Q4W
responder rate · % of participants
No placebo or comparator arm
NCT05896748 · Phase 3 · registry result, not featured evidence · combination
show 2 more results
99% (n=93) @ 8wk400 mg + 600 mg Q4W
NCT05896748 · Phase 3 · registry result, not featured evidence · combination
90% (n=93) @ 12wk400 mg + 600 mg Q4W
NCT05896748 · Phase 3 · registry result, not featured evidence · combination
HIV-1 RNA Ge50 Copies 0% (n=93) @ 4wk400 mg + 600 mg Q4W
responder rate · % of participants
No placebo or comparator arm
NCT05896748 · Phase 3 · registry result, not featured evidence · combination
show 2 more results
1.1% (n=93) @ 8wk400 mg + 600 mg Q4W
NCT05896748 · Phase 3 · registry result, not featured evidence · combination
2.2% (n=93) @ 12wk400 mg + 600 mg Q4W
NCT05896748 · Phase 3 · registry result, not featured evidence · combination
Virologic Failure 0% (n=93)400 mg + 600 mg Q4W
responder rate · % of participants
No placebo or comparator arm
NCT05896748 · Phase 3 · registry result, not featured evidence · combination
show 1 more result
0% (n=115)
NCT04001803 · Phase 3 · registry result, not featured evidence
HIV-1 RNA Less Than 50 Copies 99% (n=430) @ 4.33wk
responder rate · % of participants
No placebo or comparator arm
NCT04399551 · Phase 3 · registry result, not featured evidence
show 4 more results
96% (n=430) @ 8.67wk
NCT04399551 · Phase 3 · registry result, not featured evidence
93% (n=430) @ 17.33wk
NCT04399551 · Phase 3 · registry result, not featured evidence
86% (n=430) @ 34.67wk
NCT04399551 · Phase 3 · registry result, not featured evidence
87% (n=430) @ 52wk
NCT04399551 · Phase 3 · registry result, not featured evidence
Virologic Failure 0% (n=430) @ 4.33wk
event count · % of participants
No placebo or comparator arm
NCT04399551 · Phase 3 · registry result, not featured evidence · converted to % from 0 Participants as posted
show 6 more results
0% (n=430) @ 8.67wk*
NCT04399551 · Phase 3 · registry result, not featured evidence · converted to % from 0 Participants as posted
0% (n=430) @ 17.33wk*
NCT04399551 · Phase 3 · registry result, not featured evidence · converted to % from 0 Participants as posted
0% (n=430) @ 26wk*
NCT04399551 · Phase 3 · registry result, not featured evidence · converted to % from 0 Participants as posted
0% (n=430) @ 34.67wk*
NCT04399551 · Phase 3 · registry result, not featured evidence · converted to % from 0 Participants as posted
0.2% (n=430) @ 43.33wk*
NCT04399551 · Phase 3 · registry result, not featured evidence · converted to % from 1 Participants as posted
0% (n=430) @ 52wk*
NCT04399551 · Phase 3 · registry result, not featured evidence · converted to % from 0 Participants as posted
Virologic Failure 0.07 Cumulative probability @ 44wk
absolute value · Cumulative probability
No placebo or comparator arm
NCT03739996 · Phase 2 · registry result, not featured evidence · combination
show 1 more result
0.04 Cumulative probability @ 24wk
NCT03739996 · Phase 2 · registry result, not featured evidence · combination
Treatment Failure 0.14 Cumulative probability @ 44wk
absolute value · Cumulative probability
No placebo or comparator arm
NCT03739996 · Phase 2 · registry result, not featured evidence · combination
show 1 more result
0.2 Cumulative probability @ 44wk
NCT03739996 · Phase 2 · registry result, not featured evidence · combination
Virologic Failure Rate 50 0.13 Cumulative probability @ 44wk
absolute value · Cumulative probability
No placebo or comparator arm
NCT03739996 · Phase 2 · registry result, not featured evidence · combination
show 1 more result
0.12 Cumulative probability @ 24wk
NCT03739996 · Phase 2 · registry result, not featured evidence · combination
Virologic Failure Rate 50 9.9% (n=71) @ 44wk
event count · % of participants
No placebo or comparator arm
HIV-1 RNA ≥ 50 copies/mL on treatment
NCT03739996 · Phase 2 · registry result, not featured evidence · combination · converted to % from 7 Participants as posted
Virologic Response 50 Copies Snapshot 81.7% (n=71) @ 44wk
responder rate · % of participants
No placebo or comparator arm
HIV-1 RNA < 50 copies/mL on treatment
NCT03739996 · Phase 2 · registry result, not featured evidence · combination · converted to % from 58 Participants as posted
HIV-1 RNA Less Than 50 Copies 94% (n=115) vs 91% (n=56) CAB 30 mg+ABC/3TC @ 32wkIM-Q4W
responder rate · % of participants
Maintenance
NCT02120352 · Phase 2 · registry result, not featured evidence · combination
show 125 more results
95% (n=115) vs 91% (n=56) CAB 30 mg+ABC/3TC @ 32wkIM-Q8W
NCT02120352 · Phase 2 · registry result, not featured evidence · combination
80% (n=60) vs 71% (n=62) Efavirenz @ 48wk30 mg
NCT01641809 · Phase 2 · registry result, not featured evidence · pooled
85% (n=60) vs 74% (n=62) Efavirenz @ 24wk30 mg
NCT01641809 · Phase 2 · registry result, not featured evidence · pooled
75% (n=60) vs 66% (n=62) Efavirenz @ 26wk30 mg
NCT01641809 · Phase 2 · registry result, not featured evidence · pooled
78% (n=60) vs 69% (n=62) Efavirenz @ 28wk30 mg
NCT01641809 · Phase 2 · registry result, not featured evidence · pooled
80% (n=60) vs 69% (n=62) Efavirenz @ 32wk30 mg
NCT01641809 · Phase 2 · registry result, not featured evidence · pooled
82% (n=60) vs 71% (n=62) Efavirenz @ 36wk30 mg
NCT01641809 · Phase 2 · registry result, not featured evidence · pooled
82% (n=60) vs 68% (n=62) Efavirenz @ 40wk30 mg
NCT01641809 · Phase 2 · registry result, not featured evidence · pooled
80% (n=60) vs 71% (n=62) Efavirenz @ 48wk30 mg
NCT01641809 · Phase 2 · registry result, not featured evidence · pooled
73% (n=60) vs 68% (n=62) Efavirenz @ 60wk30 mg
NCT01641809 · Phase 2 · registry result, not featured evidence · pooled
73% (n=60) vs 68% (n=62) Efavirenz @ 72wk30 mg
NCT01641809 · Phase 2 · registry result, not featured evidence · pooled
75% (n=60) vs 68% (n=62) Efavirenz @ 84wk30 mg
NCT01641809 · Phase 2 · registry result, not featured evidence · pooled
75% (n=60) vs 63% (n=62) Efavirenz @ 96wk30 mg
NCT01641809 · Phase 2 · registry result, not featured evidence · pooled
72% (n=60) vs 0% (n=62) Efavirenz @ 108wk30 mg
NCT01641809 · Phase 2 · registry result, not featured evidence · pooled
73% (n=60) vs 0% (n=62) Efavirenz @ 120wk30 mg
NCT01641809 · Phase 2 · registry result, not featured evidence · pooled
70% (n=60) vs 0% (n=62) Efavirenz @ 132wk30 mg
NCT01641809 · Phase 2 · registry result, not featured evidence · pooled
67% (n=60) vs 0% (n=62) Efavirenz @ 144wk30 mg
NCT01641809 · Phase 2 · registry result, not featured evidence · pooled
63% (n=60) vs 0% (n=62) Efavirenz @ 156wk30 mg
NCT01641809 · Phase 2 · registry result, not featured evidence · pooled
65% (n=60) vs 0% (n=62) Efavirenz @ 168wk30 mg
NCT01641809 · Phase 2 · registry result, not featured evidence · pooled
67% (n=60) vs 0% (n=62) Efavirenz @ 180wk30 mg
NCT01641809 · Phase 2 · registry result, not featured evidence · pooled
65% (n=60) vs 0% (n=62) Efavirenz @ 192wk30 mg
NCT01641809 · Phase 2 · registry result, not featured evidence · pooled
62% (n=60) vs 0% (n=62) Efavirenz @ 204wk30 mg
NCT01641809 · Phase 2 · registry result, not featured evidence · pooled
63% (n=60) vs 0% (n=62) Efavirenz @ 216wk30 mg
NCT01641809 · Phase 2 · registry result, not featured evidence · pooled
63% (n=60) vs 0% (n=62) Efavirenz @ 228wk30 mg
NCT01641809 · Phase 2 · registry result, not featured evidence · pooled
62% (n=60) vs 0% (n=62) Efavirenz @ 240wk30 mg
NCT01641809 · Phase 2 · registry result, not featured evidence · pooled
62% (n=60) vs 0% (n=62) Efavirenz @ 252wk30 mg
NCT01641809 · Phase 2 · registry result, not featured evidence · pooled
62% (n=60) vs 0% (n=62) Efavirenz @ 264wk30 mg
NCT01641809 · Phase 2 · registry result, not featured evidence · pooled
62% (n=60) vs 0% (n=62) Efavirenz @ 276wk30 mg
NCT01641809 · Phase 2 · registry result, not featured evidence · pooled
62% (n=60) vs 0% (n=62) Efavirenz @ 288wk30 mg
NCT01641809 · Phase 2 · registry result, not featured evidence · pooled
60% (n=60) vs 0% (n=62) Efavirenz @ 300wk30 mg
NCT01641809 · Phase 2 · registry result, not featured evidence · pooled
52% (n=60) vs 0% (n=62) Efavirenz @ 312wk30 mg
NCT01641809 · Phase 2 · registry result, not featured evidence · pooled
94% (n=53) vs 96% (n=47) Efavirenz @ 24wk30 mg
NCT01641809 · Phase 2 · registry result, not featured evidence · pooled
85% (n=53) vs 87% (n=47) Efavirenz @ 26wk30 mg
NCT01641809 · Phase 2 · registry result, not featured evidence · pooled
89% (n=53) vs 91% (n=47) Efavirenz @ 28wk30 mg
NCT01641809 · Phase 2 · registry result, not featured evidence · pooled
91% (n=53) vs 91% (n=47) Efavirenz @ 32wk30 mg
NCT01641809 · Phase 2 · registry result, not featured evidence · pooled
92% (n=53) vs 94% (n=47) Efavirenz @ 36wk30 mg
NCT01641809 · Phase 2 · registry result, not featured evidence · pooled
92% (n=53) vs 89% (n=47) Efavirenz @ 40wk30 mg
NCT01641809 · Phase 2 · registry result, not featured evidence · pooled
91% (n=53) vs 94% (n=47) Efavirenz @ 48wk30 mg
NCT01641809 · Phase 2 · registry result, not featured evidence · pooled
83% (n=53) vs 89% (n=47) Efavirenz @ 60wk30 mg
NCT01641809 · Phase 2 · registry result, not featured evidence · pooled
83% (n=53) vs 89% (n=47) Efavirenz @ 72wk30 mg
NCT01641809 · Phase 2 · registry result, not featured evidence · pooled
85% (n=53) vs 89% (n=47) Efavirenz @ 84wk30 mg
NCT01641809 · Phase 2 · registry result, not featured evidence · pooled
85% (n=53) vs 83% (n=47) Efavirenz @ 96wk30 mg
NCT01641809 · Phase 2 · registry result, not featured evidence · pooled
87% (n=61) vs 71% (n=62) Efavirenz @ 48wk60 mg
NCT01641809 · Phase 2 · registry result, not featured evidence · pooled
87% (n=61) vs 74% (n=62) Efavirenz @ 24wk60 mg
NCT01641809 · Phase 2 · registry result, not featured evidence · pooled
85% (n=61) vs 66% (n=62) Efavirenz @ 26wk60 mg
NCT01641809 · Phase 2 · registry result, not featured evidence · pooled
85% (n=61) vs 69% (n=62) Efavirenz @ 28wk60 mg
NCT01641809 · Phase 2 · registry result, not featured evidence · pooled
87% (n=61) vs 69% (n=62) Efavirenz @ 32wk60 mg
NCT01641809 · Phase 2 · registry result, not featured evidence · pooled
85% (n=61) vs 71% (n=62) Efavirenz @ 36wk60 mg
NCT01641809 · Phase 2 · registry result, not featured evidence · pooled
85% (n=61) vs 68% (n=62) Efavirenz @ 40wk60 mg
NCT01641809 · Phase 2 · registry result, not featured evidence · pooled
87% (n=61) vs 71% (n=62) Efavirenz @ 48wk60 mg
NCT01641809 · Phase 2 · registry result, not featured evidence · pooled
85% (n=61) vs 68% (n=62) Efavirenz @ 60wk60 mg
NCT01641809 · Phase 2 · registry result, not featured evidence · pooled
85% (n=61) vs 68% (n=62) Efavirenz @ 72wk60 mg
NCT01641809 · Phase 2 · registry result, not featured evidence · pooled
85% (n=61) vs 68% (n=62) Efavirenz @ 84wk60 mg
NCT01641809 · Phase 2 · registry result, not featured evidence · pooled
84% (n=61) vs 63% (n=62) Efavirenz @ 96wk60 mg
NCT01641809 · Phase 2 · registry result, not featured evidence · pooled
80% (n=61) vs 0% (n=62) Efavirenz @ 108wk60 mg
NCT01641809 · Phase 2 · registry result, not featured evidence · pooled
80% (n=61) vs 0% (n=62) Efavirenz @ 120wk60 mg
NCT01641809 · Phase 2 · registry result, not featured evidence · pooled
80% (n=61) vs 0% (n=62) Efavirenz @ 132wk60 mg
NCT01641809 · Phase 2 · registry result, not featured evidence · pooled
77% (n=61) vs 0% (n=62) Efavirenz @ 144wk60 mg
NCT01641809 · Phase 2 · registry result, not featured evidence · pooled
80% (n=61) vs 0% (n=62) Efavirenz @ 156wk60 mg
NCT01641809 · Phase 2 · registry result, not featured evidence · pooled
75% (n=61) vs 0% (n=62) Efavirenz @ 168wk60 mg
NCT01641809 · Phase 2 · registry result, not featured evidence · pooled
75% (n=61) vs 0% (n=62) Efavirenz @ 180wk60 mg
NCT01641809 · Phase 2 · registry result, not featured evidence · pooled
74% (n=61) vs 0% (n=62) Efavirenz @ 192wk60 mg
NCT01641809 · Phase 2 · registry result, not featured evidence · pooled
75% (n=61) vs 0% (n=62) Efavirenz @ 204wk60 mg
NCT01641809 · Phase 2 · registry result, not featured evidence · pooled
77% (n=61) vs 0% (n=62) Efavirenz @ 216wk60 mg
NCT01641809 · Phase 2 · registry result, not featured evidence · pooled
75% (n=61) vs 0% (n=62) Efavirenz @ 228wk60 mg
NCT01641809 · Phase 2 · registry result, not featured evidence · pooled
74% (n=61) vs 0% (n=62) Efavirenz @ 240wk60 mg
NCT01641809 · Phase 2 · registry result, not featured evidence · pooled
75% (n=61) vs 0% (n=62) Efavirenz @ 252wk60 mg
NCT01641809 · Phase 2 · registry result, not featured evidence · pooled
75% (n=61) vs 0% (n=62) Efavirenz @ 264wk60 mg
NCT01641809 · Phase 2 · registry result, not featured evidence · pooled
70% (n=61) vs 0% (n=62) Efavirenz @ 276wk60 mg
NCT01641809 · Phase 2 · registry result, not featured evidence · pooled
74% (n=61) vs 0% (n=62) Efavirenz @ 288wk60 mg
NCT01641809 · Phase 2 · registry result, not featured evidence · pooled
70% (n=61) vs 0% (n=62) Efavirenz @ 300wk60 mg
NCT01641809 · Phase 2 · registry result, not featured evidence · pooled
70% (n=61) vs 0% (n=62) Efavirenz @ 312wk60 mg
NCT01641809 · Phase 2 · registry result, not featured evidence · pooled
96% (n=55) vs 96% (n=47) Efavirenz @ 24wk60 mg
NCT01641809 · Phase 2 · registry result, not featured evidence · pooled
95% (n=55) vs 87% (n=47) Efavirenz @ 26wk60 mg
NCT01641809 · Phase 2 · registry result, not featured evidence · pooled
95% (n=55) vs 91% (n=47) Efavirenz @ 28wk60 mg
NCT01641809 · Phase 2 · registry result, not featured evidence · pooled
96% (n=55) vs 91% (n=47) Efavirenz @ 32wk60 mg
NCT01641809 · Phase 2 · registry result, not featured evidence · pooled
95% (n=55) vs 94% (n=47) Efavirenz @ 36wk60 mg
NCT01641809 · Phase 2 · registry result, not featured evidence · pooled
95% (n=55) vs 89% (n=47) Efavirenz @ 40wk60 mg
NCT01641809 · Phase 2 · registry result, not featured evidence · pooled
96% (n=55) vs 94% (n=47) Efavirenz @ 48wk60 mg
NCT01641809 · Phase 2 · registry result, not featured evidence · pooled
95% (n=55) vs 89% (n=47) Efavirenz @ 60wk60 mg
NCT01641809 · Phase 2 · registry result, not featured evidence · pooled
95% (n=55) vs 89% (n=47) Efavirenz @ 72wk60 mg
NCT01641809 · Phase 2 · registry result, not featured evidence · pooled
95% (n=55) vs 89% (n=47) Efavirenz @ 84wk60 mg
NCT01641809 · Phase 2 · registry result, not featured evidence · pooled
93% (n=55) vs 83% (n=47) Efavirenz @ 96wk60 mg
NCT01641809 · Phase 2 · registry result, not featured evidence · pooled
80% (n=60) vs 71% (n=62) Efavirenz @ 48wk10 mg
NCT01641809 · Phase 2 · registry result, not featured evidence · pooled
87% (n=60) vs 74% (n=62) Efavirenz @ 24wk10 mg
NCT01641809 · Phase 2 · registry result, not featured evidence · pooled
78% (n=60) vs 66% (n=62) Efavirenz @ 26wk10 mg
NCT01641809 · Phase 2 · registry result, not featured evidence · pooled
85% (n=60) vs 69% (n=62) Efavirenz @ 28wk10 mg
NCT01641809 · Phase 2 · registry result, not featured evidence · pooled
83% (n=60) vs 69% (n=62) Efavirenz @ 32wk10 mg
NCT01641809 · Phase 2 · registry result, not featured evidence · pooled
85% (n=60) vs 71% (n=62) Efavirenz @ 36wk10 mg
NCT01641809 · Phase 2 · registry result, not featured evidence · pooled
83% (n=60) vs 68% (n=62) Efavirenz @ 40wk10 mg
NCT01641809 · Phase 2 · registry result, not featured evidence · pooled
80% (n=60) vs 71% (n=62) Efavirenz @ 48wk10 mg
NCT01641809 · Phase 2 · registry result, not featured evidence · pooled
78% (n=60) vs 68% (n=62) Efavirenz @ 60wk10 mg
NCT01641809 · Phase 2 · registry result, not featured evidence · pooled
72% (n=60) vs 68% (n=62) Efavirenz @ 72wk10 mg
NCT01641809 · Phase 2 · registry result, not featured evidence · pooled
72% (n=60) vs 68% (n=62) Efavirenz @ 84wk10 mg
NCT01641809 · Phase 2 · registry result, not featured evidence · pooled
68% (n=60) vs 63% (n=62) Efavirenz @ 96wk10 mg
NCT01641809 · Phase 2 · registry result, not featured evidence · pooled
68% (n=60) vs 0% (n=62) Efavirenz @ 108wk10 mg
NCT01641809 · Phase 2 · registry result, not featured evidence · pooled
65% (n=60) vs 0% (n=62) Efavirenz @ 120wk10 mg
NCT01641809 · Phase 2 · registry result, not featured evidence · pooled
62% (n=60) vs 0% (n=62) Efavirenz @ 132wk10 mg
NCT01641809 · Phase 2 · registry result, not featured evidence · pooled
58% (n=60) vs 0% (n=62) Efavirenz @ 144wk10 mg
NCT01641809 · Phase 2 · registry result, not featured evidence · pooled
58% (n=60) vs 0% (n=62) Efavirenz @ 156wk10 mg
NCT01641809 · Phase 2 · registry result, not featured evidence · pooled
57% (n=60) vs 0% (n=62) Efavirenz @ 168wk10 mg
NCT01641809 · Phase 2 · registry result, not featured evidence · pooled
58% (n=60) vs 0% (n=62) Efavirenz @ 180wk10 mg
NCT01641809 · Phase 2 · registry result, not featured evidence · pooled
57% (n=60) vs 0% (n=62) Efavirenz @ 192wk10 mg
NCT01641809 · Phase 2 · registry result, not featured evidence · pooled
55% (n=60) vs 0% (n=62) Efavirenz @ 204wk10 mg
NCT01641809 · Phase 2 · registry result, not featured evidence · pooled
55% (n=60) vs 0% (n=62) Efavirenz @ 216wk10 mg
NCT01641809 · Phase 2 · registry result, not featured evidence · pooled
53% (n=60) vs 0% (n=62) Efavirenz @ 228wk10 mg
NCT01641809 · Phase 2 · registry result, not featured evidence · pooled
50% (n=60) vs 0% (n=62) Efavirenz @ 240wk10 mg
NCT01641809 · Phase 2 · registry result, not featured evidence · pooled
52% (n=60) vs 0% (n=62) Efavirenz @ 252wk10 mg
NCT01641809 · Phase 2 · registry result, not featured evidence · pooled
53% (n=60) vs 0% (n=62) Efavirenz @ 264wk10 mg
NCT01641809 · Phase 2 · registry result, not featured evidence · pooled
52% (n=60) vs 0% (n=62) Efavirenz @ 276wk10 mg
NCT01641809 · Phase 2 · registry result, not featured evidence · pooled
50% (n=60) vs 0% (n=62) Efavirenz @ 288wk10 mg
NCT01641809 · Phase 2 · registry result, not featured evidence · pooled
52% (n=60) vs 0% (n=62) Efavirenz @ 300wk10 mg
NCT01641809 · Phase 2 · registry result, not featured evidence · pooled
52% (n=60) vs 0% (n=62) Efavirenz @ 312wk10 mg
NCT01641809 · Phase 2 · registry result, not featured evidence · pooled
96% (n=52) vs 96% (n=47) Efavirenz @ 24wk10 mg
NCT01641809 · Phase 2 · registry result, not featured evidence · pooled
90% (n=52) vs 87% (n=47) Efavirenz @ 26wk10 mg
NCT01641809 · Phase 2 · registry result, not featured evidence · pooled
98% (n=52) vs 91% (n=47) Efavirenz @ 28wk10 mg
NCT01641809 · Phase 2 · registry result, not featured evidence · pooled
96% (n=52) vs 91% (n=47) Efavirenz @ 32wk10 mg
NCT01641809 · Phase 2 · registry result, not featured evidence · pooled
98% (n=52) vs 94% (n=47) Efavirenz @ 36wk10 mg
NCT01641809 · Phase 2 · registry result, not featured evidence · pooled
96% (n=52) vs 89% (n=47) Efavirenz @ 40wk10 mg
NCT01641809 · Phase 2 · registry result, not featured evidence · pooled
92% (n=52) vs 94% (n=47) Efavirenz @ 48wk10 mg
NCT01641809 · Phase 2 · registry result, not featured evidence · pooled
90% (n=52) vs 89% (n=47) Efavirenz @ 60wk10 mg
NCT01641809 · Phase 2 · registry result, not featured evidence · pooled
83% (n=52) vs 89% (n=47) Efavirenz @ 72wk10 mg
NCT01641809 · Phase 2 · registry result, not featured evidence · pooled
83% (n=52) vs 89% (n=47) Efavirenz @ 84wk10 mg
NCT01641809 · Phase 2 · registry result, not featured evidence · pooled
79% (n=52) vs 83% (n=47) Efavirenz @ 96wk10 mg
NCT01641809 · Phase 2 · registry result, not featured evidence · pooled
98% (n=90) vs 100% (n=7) DTG + RPV @ 48wkQ2M
NCT03639311 · Phase 2 · registry result, not featured evidence · combination
Virologic Failure 0% (n=115) vs 1.8% (n=56) CAB 30 mg+ABC/3TC @ 32wkIM-Q4W
event count · % of participants
Maintenance
NCT02120352 · Phase 2 · registry result, not featured evidence · combination · converted to % from 0 Participants as posted
show 6 more results
0% (n=115) vs 1.8% (n=56) CAB 30 mg+ABC/3TC @ 32wk*IM-Q4W
NCT02120352 · Phase 2 · registry result, not featured evidence · combination · converted to % from 0 Participants as posted
0% (n=115) vs 1.8% (n=56) CAB 30 mg+ABC/3TC @ 48wk*IM-Q4W
NCT02120352 · Phase 2 · registry result, not featured evidence · combination · converted to % from 0 Participants as posted
0.9% (n=115) vs 1.8% (n=56) CAB 30 mg+ABC/3TC @ 32wk*IM-Q8W
NCT02120352 · Phase 2 · registry result, not featured evidence · combination · converted to % from 1 Participants as posted
0.9% (n=115) vs 1.8% (n=56) CAB 30 mg+ABC/3TC @ 32wk*IM-Q8W
NCT02120352 · Phase 2 · registry result, not featured evidence · combination · converted to % from 1 Participants as posted
1.7% (n=115) vs 1.8% (n=56) CAB 30 mg+ABC/3TC @ 48wk*IM-Q8W
NCT02120352 · Phase 2 · registry result, not featured evidence · combination · converted to % from 2 Participants as posted
1.1% (n=90) vs 0% (n=7) DTG + RPV*Q2M
NCT03639311 · Phase 2 · registry result, not featured evidence · combination · converted to % from 1 Participants as posted

+ 168 further endpoints in the CSV export.

Raltegravir

HIV RNA Less Than 400 Copies 77.3% (n=229) vs 42.9% (n=119) placebo @ 16wk400 mg b.i.d.
responder rate · % of participants
Induction
NCT00293254 · Phase 3 · combination
show 1 more result
77.7% (n=229) vs 41% (n=117) placebo @ 16wk400 mg b.i.d
NCT00293267 · Phase 3 · combination
HIV RNA Less Than 400 Copies 71.1% (n=228) vs 37.8% (n=119) placebo @ 48wk400 mg b.i.d.
responder rate · % of participants
Maintenance
NCT00293254 · Phase 3 · combination
show 3 more results
50.2% (n=229) vs 21% (n=119) placebo @ 156wk400 mg b.i.d.
NCT00293254 · Phase 3 · combination
73.6% (n=231) vs 36.4% (n=118) placebo @ 48wk400 mg b.i.d
NCT00293267 · Phase 3 · combination
57.3% (n=232) vs 25.6% (n=117) placebo @ 156wk400 mg b.i.d
NCT00293267 · Phase 3 · combination
HIV RNA Less Than 400 Copies 45.7% (n=230) vs 13.4% (n=119) placebo @ 240wk400 mg b.i.d.
responder rate · % of participants
Extension (open-label)
NCT00293254 · Phase 3 · combination
show 1 more result
45.3% (n=232) vs 20.3% (n=118) placebo @ 240wk400 mg b.i.d
NCT00293267 · Phase 3 · combination
HIV RNA Less Than 50 Copies 62% (n=229) vs 36.1% (n=119) placebo @ 16wk400 mg b.i.d.
responder rate · % of participants
Induction
NCT00293254 · Phase 3 · combination
show 1 more result
61.6% (n=229) vs 33.3% (n=117) placebo @ 16wk400 mg b.i.d
NCT00293267 · Phase 3 · combination
HIV RNA Less Than 50 Copies 59.6% (n=228) vs 34.5% (n=119) placebo @ 48wk400 mg b.i.d.
responder rate · % of participants
Maintenance
NCT00293254 · Phase 3 · combination
show 3 more results
47.6% (n=229) vs 17.6% (n=119) placebo @ 156wk400 mg b.i.d.
NCT00293254 · Phase 3 · combination
64.5% (n=231) vs 31.4% (n=118) placebo @ 48wk400 mg b.i.d
NCT00293267 · Phase 3 · combination
53.4% (n=232) vs 25.6% (n=117) placebo @ 156wk400 mg b.i.d
NCT00293267 · Phase 3 · combination
HIV RNA Less Than 50 Copies 41.3% (n=230) vs 13.4% (n=119) placebo @ 240wk400 mg b.i.d.
responder rate · % of participants
Extension (open-label)
NCT00293254 · Phase 3 · combination
show 1 more result
42.2% (n=232) vs 18.6% (n=118) placebo @ 240wk400 mg b.i.d
NCT00293267 · Phase 3 · combination
Without Loss of Virologic 44.3% (n=230) vs 17.6% (n=119) placebo @ 156wk400 mg b.i.d.
responder rate · % of participants
Maintenance
NCT00293254 · Phase 3 · combination
HIV-1 RNA -1.92 vs -1.06 placebo copies/mL @ 16wk400 mg b.i.d.
absolute change · copies/mL
Induction
NCT00293254 · Phase 3 · combination
show 1 more result
-1.85 vs -0.78 placebo copies/mL @ 16wk400 mg b.i.d
NCT00293267 · Phase 3 · combination
HIV-1 RNA -1.75 vs -0.87 placebo copies/mL @ 48wk400 mg b.i.d.
absolute change · copies/mL
Maintenance
NCT00293254 · Phase 3 · combination
show 4 more results
-1.37 vs -0.52 placebo copies/mL @ 156wk400 mg b.i.d.
NCT00293254 · Phase 3 · combination
-1.67 vs -0.68 placebo copies/mL @ 48wk400 mg b.i.d
NCT00293267 · Phase 3 · combination
-1.44 vs -0.51 placebo copies/mL @ 156wk400 mg b.i.d
NCT00293267 · Phase 3 · combination
-3.05 vs -3.29 Atazanavir copies/mL @ 48wk
NCT00762892 · Phase 4 · registry result, not featured evidence
HIV-1 RNA -1.31 vs -0.41 placebo copies/mL @ 240wk400 mg b.i.d.
absolute change · copies/mL
Extension (open-label)
NCT00293254 · Phase 3 · combination
show 1 more result
-1.24 vs -0.45 placebo copies/mL @ 240wk400 mg b.i.d
NCT00293267 · Phase 3 · combination
CD4+ 172.1 vs 54.1 placebo cells/uL @ 240wk400 mg b.i.d.
absolute change · cells/uL
Extension (open-label)
NCT00293254 · Phase 3 · combination
show 1 more result
193.6 vs 68.2 placebo cells/uL @ 240wk400 mg b.i.d
NCT00293267 · Phase 3 · combination
HIV-1 RNA Less Than 400 Copies Per 86.1% (n=280) vs 81.9% (n=281) Efavirenz @ 48wk400 mg b.i.d.
event count · % of participants
Maintenance
NCT00369941 · Phase 3 · converted to % from 241 Participants as posted
show 7 more results
90% (n=280) vs 85.8% (n=281) Efavirenz @ 48wk*400 mg b.i.d.
NCT00369941 · Phase 3 · converted to % from 252 Participants as posted
81.1% (n=281) vs 78.7% (n=282) Efavirenz @ 96wk*400 mg b.i.d.
NCT00369941 · Phase 3 · converted to % from 228 Participants as posted
85.4% (n=281) vs 81.2% (n=282) Efavirenz @ 96wk*400 mg b.i.d.
NCT00369941 · Phase 3 · converted to % from 240 Participants as posted
75.4% (n=281) vs 68.1% (n=282) Efavirenz @ 156wk*400 mg b.i.d.
NCT00369941 · Phase 3 · converted to % from 212 Participants as posted
79.7% (n=281) vs 72% (n=282) Efavirenz @ 156wk*400 mg b.i.d.
NCT00369941 · Phase 3 · converted to % from 224 Participants as posted
71% (n=279) vs 61.3% (n=279) Efavirenz @ 240wk*400 mg b.i.d.
NCT00369941 · Phase 3 · converted to % from 198 Participants as posted
73.8% (n=279) vs 64.9% (n=279) Efavirenz @ 240wk*400 mg b.i.d.
NCT00369941 · Phase 3 · converted to % from 206 Participants as posted

+ 22 further endpoints in the CSV export.

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Cabotegravir/rilpivirine (Cabenuva)'s landscape · Raltegravir's landscape